

66/01/60



Docket No. 52209-APCT-US/JPW/JML

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Assistant Commissioner for Patents
Washington, D.C. 20231

S I R:

Transmitted herewith for filing are the specification and claims of the patent application of:

David M. Stern and Shi Du Yan
Inventor(s)Intracellular Amyloid-Beta Peptide Binding (ERAB) Polypeptide
Title of Invention

Also enclosed are:

☒ 22 sheet(s) of ☐ informal ☒ formal drawings.☒ Oath or declaration of Applicant(s)☒ A power of attorney☒ An assignment of the invention to The Trustees of Columbia University in the City of New York☒ A Preliminary Amendment☒ A verified statement to establish small entity status under 37 C.F.R. §1.9 and §1.27.

The filing fee is calculated as follows:


CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT

	NUMBER FILED		NUMBER EXTRA*		RATE		FEE	
					SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
Total Claims	25-20	=	5	X	\$9.00	\$18.00	= \$ 45.00	\$
Independent Claims	7-3	=	4	X	\$39.00	\$78.00	= \$ 156.00	\$
Multiple Dependent Claims Presented: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No					\$130.00	\$260.00	= \$ 0	\$
*If the different in Col. 1 is less than zero, enter "0" in Col. 2					BASIC FEE		\$380.00	\$760.00
					TOTAL FEE		\$581.00	\$

Jc678 U.S. PTO
09/394204
09/10/99

- ☒ A check in the amount of \$ 581.00 to cover the filing fee.
- ☐ Please charge Deposit Account No. _____ in the amount of \$ _____.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the following or credit any over-payment to Account No. 03-3125:
- ☒ Filing fees under 37 C.F.R. §1.16.
- ☒ Patent application processing fees under 37 C.F.R. §1.17.
- ☐ The issue fee set in 37 C.F.R. §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. §1.311(b).
- ☒ Three copies of this sheet are enclosed.
- ☒ A certified copy of previously filed foreign application No. _____ filed in _____ on _____. Applicant(s) hereby claim priority based upon this aforementioned foreign application under 35 U.S.C. §119.
- ☒ Other (identify) One (1) loose set of formal drawings for Figures 1A - 7 (22 sheets); Express Mail Certificate of Mailing bearing Express Mail label no. EL278887005US dated September 10, 1999; Form PTO-1595 (Substitute) Requesting Recordation of Assignment (in duplicate) with authorization to charge Deposit Account

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Applicant or Patentee: David M. Stern and Shi Du Yan Attorney's
Serial or Patent No.: Not Yet Known Docket No 52209-APT-US/JW/
Filed or Issued: Herewith M
Title of Invention or Patent: Intracellular Amyloid-Beta Binding (ERAB) Polypeptide

VERIFIED STATEMENT (DECLARATION) CLAIMING
SMALL ENTITY STATUS UNDER 37 C.F.R. §1.9(f)
AND §1.27(d) - NONPROFIT ORGANIZATION

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

Name of Organization: The Trustees of Columbia University in the City of New York

Address of Organization: West 116th Street and Broadway, New York, New York 10027,
U.S.A.

TYPE OF ORGANIZATION:

☒ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION
☐ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE 26 U.S.C. §§501(a) and 501(c)(3)
☐ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA
NAME OF STATE: _____
CITATION OF STATUTE: _____
☐ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE 26 U.S.C. §§501(a) and 501(c)(3) IF LOCATED IN THE UNITED STATES OF AMERICA
☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA
NAME OF STATE: _____
CITATION OF STATUTE: _____

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 C.F.R. §1.9(e)* for purposes of paying reduced fees under 35 U.S.C. §41(a) and 41(b), with regard to the invention entitled Intracellular Amyloid-Beta Binding (ERAB) Polypeptide

by inventor(s) David M. Stern and Shi Du Yan

described in:

☒ the specification filed herewith
☐ application serial no. _____ filed _____
☐ patent no. _____ issued _____

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the nonprofit organization are not exclusive each individual, concern, or organization known to have rights to the invention is listed below^a and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 C.F.R. §1.9(d)* or a nonprofit organization under 37 C.F.R. 1.9(e)*

^a NOTE: Separate verified statements are required from each person, concern, or organization having rights to the invention averring to their status as small entities. 37 C.F.R. §1.27.


Name: N/A

Address: _____

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. 37 C.F.R. §1.28(b)*.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent issuing thereon, or any patent to which this verified statement is directed.

Name of Person Signing: Mr. Jack M. Granowitz
Title In Organization: Executive Director, Columbia Innovation Enterprise
Address: Columbia University, Engineering Terrace - Suite 363, Amsterdam
Avenue & West 120th Street, New York, New York 10027, U.S.A.
Signature: 
Date of Signature: 9/10/99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : David M. Stern and Shi Du Yan
U.S. Serial No. : Not Yet Known (Continuation Application
of PCT/US98/04915, filed 12 March 1998)
Filed : Herewith
For : INTRACELLULAR AMYLOID-BETA PEPTIDE
BINDING (ERAB) POLYPEPTIDE

1185 Avenue Of The Americas
New York, New York 10036
September 10, 1999

Assistant Commissioner for Patents
Washington, D.C. 20231
Box: Patent Application

Sir:

PRELIMINARY AMENDMENT TO THE ACCOMPANYING CONTINUATION
APPLICATION FILED UNDER 37 C.F.R. §1.53

Applicants request that the following amendment be made in the
above-identified application:

In the Specification:

On page 1, after the title, please delete the first sentence and
insert the following new sentence:

--This application is a continuation of PCT International
Application No. PCT/US98/04915, filed 12 March 1998,
designating the United States of America, which is claiming
priority of U.S. Serial No. 08/815,225, filed March 12,
1997, the contents of which are hereby incorporated by
reference into the present application.--

Applicants: David M. Stern and Shi Du Yan
U.S. Serial No.: Not Yet Known
(Continuation of PCT/US98/04915,
filed 12 March 1998)
Filed: Herewith
Page 2

REMARKS


This application is a continuation of PCT International Application No. PCT/US98/04915, filed 12 March 1998, designating the United States of America and claiming priority of U.S. Serial No. 08/815,225, filed March 12, 1997. Accordingly, the parent application, PCT International Application No. PCT/US98/04915, is pending today in the United States of America pursuant to 35 U.S.C. §363, and the subject continuation application is co-pending therewith in fulfillment of the provisions of 35 U.S.C. §120.

By this Preliminary Amendment, applicants have hereinabove amended the specification on page 1 to insert the continuation data. Accordingly, upon entry of this Amendment, claims 1-25 are pending in this application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone at the number provided below.

No fee other than the filing fee of \$581.00 is deemed necessary in connection with this Preliminary Amendment. However, if any other fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Reg. No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

**Application
for
United States Letters Patent**

To all whom it may concern:

Be it known that David M. Stern and Shi Du Yan
have invented certain new and useful improvements in
INTRACELLULAR AMYLOID-BETA BINDING (ERAB) POLYPEPTIDE
of which the following is a full, clear and exact description.

INTRACELLULAR AMYLOID-BETA BINDING (ERAB) POLYPEPTIDE

5 This application is a continuation in part of U.S. Application Serial No. 08/815,225, filed March 12, 1997, the contents of which are hereby incorporated by reference into the present application.

10 The invention disclosed herein was made with Government support under NIH (Aging Institute) Grant No. AG 006902, from the Department of Health and Human Services. Accordingly, the U.S. Government has certain rights in this invention.

15 Throughout this application, various references are referred to by numbers within parentheses. Disclosures of these publications in their entirety are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full
20 bibliographic citation for these references may be found at the end of this application, preceding the claims, in numerical order corresponding to the numbers within parentheses.

25 Background of the Invention

Processing of the beta-amyloid precursor protein (APP) leads to a range of proteolyzed forms (1-6), some of which assemble into beta-amyloid fibrils and are cytotoxic. β -
30 amyloid moieties, such as amyloid-beta peptide ($A\beta$), are closely associated with neuronal dysfunction and death in Alzheimer's disease (AD). Increased expression of amyloid-beta peptide is linked to mutations in APP (6-10) and in presenilins (11-13), both of which occur in familial AD.
35 The mechanisms underlying the cellular stress phenotype brought about in cells by amyloid-beta peptide-derived peptides are likely related to the neurotoxicity leading to dementia. Most attention has been focussed on mechanisms by which extracellular amyloid-beta peptide exerts its effects

on cells, since the most visible accumulations of amyloid-beta peptide occur extracellularly in plaques. Amyloid-beta peptide aggregates, especially those that assemble into fibrils, can be cytotoxic by nonspecifically disturbing the integrity of cell membranes, and by elaborating reactive oxygen intermediates (14-15), thereby resulting in elevation of cytosolic calcium eventually followed by cell death (15-16). Cell surface receptors for amyloid-beta peptide (17-19) could also activate signal transduction mechanisms. The receptor RAGE, an immunoglobulin superfamily molecule, is one such neuronal cell surface docking site which binds amyloid-beta peptide and facilitates amyloid-beta peptide-mediated cellular oxidant stress (19).

Summary of the Invention

5 The present invention provides an isolated nucleic acid
encoding an endoplasmic reticulum associated amyloid-beta
peptide binding (ERAB) polypeptide. The ERAB polypeptide
may comprise human ERAB polypeptide. The present invention
provides a purified ERAB polypeptide, as well as a method
for treating a neurodegenerative condition in a subject
10 which comprises administering to the subject an agent in
amount effective to inhibit ERAB polypeptide binding to
amyloid-beta peptide so as to thereby treat the
neurodegenerative condition.

Description of the Figures

Figures 1A, 1B, 1C, 1D, 1E-1 and 1E-2. Identification and cloning of a cell-associated binding protein for amyloid-beta peptide. Fig. 1A. Schematic depiction of fragments of human amyloid precursor protein (APP) cloned into the yeast expression vector pGBT9. The line at the top designates the full-length APP cDNA (numbering is according to the Genbank sequence accession #X06989) and thickened portions indicate the region encoding A4 (APP amino acids 653 to 694). Open boxes show APP fragments encoded by the indicated plasmid fusion proteins. ATG, start codon; TAG, stop codon; E, EcoRI; S, StyI; and B, BamHI. Fig. 1B. Visualization of β -galactosidase reaction product when yeast express the two indicated constructs. The left panel of Fig. 1B demonstrates the presence of yeast on the agar and the right panel of Fig. 1B shows the same area stained for β -galactosidase reaction product. Each experiment is shown in triplicate. pA β 002 is one of three ERAB-containing clones derived from the HeLa cell MatchmakerTM cDNA library. pVA3 indicates murine p53 in pGBT9, pTD1 indicates SV40 large T-antigen in pGAD3F, and the combination of these two plasmids is used as a positive control. Fig. 1C. Quantitative analysis of β -galactosidase gene product from an experiment using the same constructs as in Fig. 1B. Fig. 1D. cDNA sequence and deduced amino acid sequence of the endoplasmic reticulum binding polypeptide (ERAB polypeptide) identified in the yeast two-hybrid system (Seq. Id. Nos. 1 and 2). Figs. 1E1-1E2. Alignment of ERAB polypeptide deduced amino acid sequence (Sequence Id. No. 3) with that for 20- β -hydroxysteroid dehydrogenase (BHD) (Seq. Id. No. 4). The boxed areas correspond to amino acid domains involved in binding of nicotinamide adenine dinucleotide (NAD). The boxed area with bold letters corresponds to the putative active center of the steroid binding domain. One dot and two dots indicated similar and identical amino acid residues, respectively. Methods: Fragments of human amyloid

precursor protein (APP) were cloned into the yeast expression vector pGBT9 (a GAL4 DNA-binding domain hybrid cloning vector; Clontech). The 3'-end of the EcoRI fragment from the APP cDNA was cloned into pGBT9 to generate pGBT/APP-23, which encodes a fusion protein comprising the C-terminus of APP (amino acids 655-751). A stop codon (TGA) was introduced after the sequence of A4 by site-directed mutagenesis and the resulting EcoRI fragment was cloned into pGBT9 to generate pBA-6, which encodes a fusion protein containing A4 peptide sequence (amino acids 3-42). A BamHI site was introduced at the beginning of A4 by PCR amplification and the resulting fragment was subcloned into the unique BamHI site of pGBT9 to generate pGBT/AB-13, the latter encoding a fusion protein with the A4 peptide sequence (amino acids 1-42). The plasmid constructs pBA-6 and pGBT/AB-13 were used as bait to screen human brain and HeLa Matchmaker libraries according to the manufacturer's instructions. Quantitative assay of β -galactosidase activity was performed using o-nitrophenyl β -D-galactopyranoside (ONPG) as substrate.

Figures 2A, 2B, 2C, 2D, 2E, 2F, and 2G. Expression of ERAB fusion protein: amyloid-beta peptide binding properties.
Fig. 2A. SDS-PAGE (12%; reduced) followed by immunoblotting of TrcHis-ERAB polypeptide (Fig. 2A, lane 1; 2 μ g) and TrcHis-chloramphenicol acetyltransferase (CAT; Fig. 2A, lane 2; 2 μ g) fusion proteins using anti-ERAB polypeptide IgG (3 μ g/ml). Figure 2A lane 3 has the same sample as in Figure 2A lane 1, except that free peptide used as immunogen was present at an \approx 25-fold molar excess over the antibody.
Figs. 2B and 2C. The indicated concentrations of TrcHis-ERAB polypeptide (Fig. 2B; or in Fig. 2C, 5 μ g/well) were incubated in microtiter wells, excess sites on the plastic surface were blocked, and a binding assay was performed by adding 125 I-amyloid-beta peptide (100 nM; 1-40) alone or in the presence of an 100-fold molar excess of unlabelled amyloid-beta peptide (1-40; Fig. 2B). In Fig. 2C, anti-ERAB polypeptide IgG (α -ERAB polypeptide; 10 μ g/ml) or nonimmune

(NI) IgG (10 μ g/ml) was added. Specific binding (that observed in wells with 125 I-amyloid-beta peptide alone minus binding observed in wells with 125 I-amyloid-beta peptide + unlabelled amyloid-beta peptide), the mean \pm SEM of quadruplicate determinations, is shown. Fig. 2D. TrcHis-ERAB polypeptide (5 μ g/well) was incubated in microtiter wells, and the binding assay was performed using the indicated concentrations of 125 I-amyloid-beta peptide (1-40) alone or in the presence of excess unlabelled amyloid-beta peptide. Binding was analyzed by nonlinear least squares analysis using the method of Klotz and Hunston (60). Fig. 2E. Competitive binding study: TrcHis-ERAB polypeptide (5 μ g/well) was incubated in microtiter wells, and the binding assay employed freshly prepared 125 I-amyloid-beta peptide (100 nM;1-40). Where indicated one of the following unlabelled competitors was added: freshly prepared synthetic amyloid-beta peptide(1-20), amyloid-beta peptide(1-40), amyloid-beta peptide(25-35), scrambled amyloid-beta peptide(25-35), amyloid-beta peptide purified from AD brain (61), Arg-Gly-Asp-Ser (Seq. ID. No. 5), or amyloid-beta peptide(1-40) incubated for 3 days at 37°C under conditions to promote aggregation (6) (in each case the competitor was added at 10 μ M). Fig. 2F and 2G. Binding of 125 I-TrcHis-ERAB polypeptide to amyloid-beta peptide(1-42) adsorbed to microtiter wells. In Fig. 2F, the indicated concentration of amyloid-beta peptide(1-42) was incubated in wells, excess sites on the plate were blocked, and the binding assay was performed by adding 125 I-TrcHis-ERAB polypeptide alone or in the presence of an 100-fold molar excess of unlabelled TrcHis-ERAB polypeptide. In Fig. 2G, the binding assay was performed in the presence of the indicated concentration of 125 I-TrcHis-ERAB polypeptide (alone or in the presence of an 100-fold molar excess of unlabelled TrcHis-ERAB polypeptide) in wells with adsorbed amyloid-beta peptide (1-42; 5 μ g/well was added). 0 indicates wells coated with albumin alone. The mean \pm SEM of specific binding of quadruplicates is shown. * indicates $p < 0.01$. Methods: A fusion protein construct was prepared by

subcloning an approximately 1116 bp EcoRI fragment (including 318 bp of 3'-untranslated sequence) into the unique EcoRI site of pTrcHis C vector (Invitrogen) to express TrcHis-ERAB polypeptide fusion protein. Following transformation of E. coli with this latter construct, the TrcHis-ERAB polypeptide fusion protein was purified as described by the manufacturer (Invitrogen). Control TrcHis-CAT construct (Invitrogen) was also used to transform E. coli and the fusion protein was purified as above. Antibody to ERAB polypeptide was prepared by immunizing rabbits with ERAB polypeptide-derived peptides, corresponding to residues 100-116 and 133-147, conjugated to keyhole limpet hemocyanin. These antibodies were demonstrated to be specific for ERAB polypeptide (see Figs. 2A-2G and description), and were used for immunoblotting, immunohistochemistry and functional studies. For immunoblotting shown in Fig. 2A, proteins were subject to reduced SDS-PAGE (12%), electrophoretic transfer to nitrocellulose, and reaction with anti-ERAB polypeptide antibody; sites of anti-ERAB polypeptide IgG binding were detected using the alkaline phosphatase method (Sigma). ¹²⁵I-amyloid-beta peptide(1-40) was radiolabelled as described (19) and ¹²⁵I-TrcHis-ERAB polypeptide polypeptide was labeled by the lactoperoxidase method (62). The latter tracer demonstrated a specific radioactivity of 2,000-2,500 cpm/ng, was >95% precipitable in trichloroacetic acid, and migrated as a single band, M_r ≈29 kDa, on SDS-PAGE. The binding assay to demonstrate direct interaction of ERAB polypeptide and amyloid-beta peptide utilized a modification of a previously described method (19). In brief, the indicated protein, ERAB polypeptide or amyloid-beta peptide, was diluted in carbonate buffer and incubated for 2 hrs at 37°C (for ERAB polypeptide) or overnight at 4°C (for amyloid-beta peptide) in Nunc MaxiSorb plates, excess sites in wells were blocked by exposure to albumin-containing solution (1% for 2 hr at 37°C), and then the radioiodinated tracer alone or in the presence of excess unlabelled material was added in minimal essential medium with bovine

serum albumin (1%; Sigma; fraction V, fatty acid-free) at 37°C. Incubation time was 3 hrs, when ^{125}I -TrcHis-ERAB polypeptide and ^{125}I -amyloid-beta peptide were the tracers, respectively. Unbound radioactivity was removed by washing wells five times with ice cold phosphate-buffered saline containing Tween 20 (0.05%), and bound radioactivity was eluted by incubation with Nonidet P-40 (1%).

Figures 3A, 3B, 3C, 3D, 3E, 3F-1 and 3F-2. Expression of ERAB polypeptide in human tissue. Figs. 3A, 3B, and 3C. Northern analysis of total RNA harvested from the indicated normal organs (Fig. 3A) or brain subregions (Figs. 3B and 3C; Clontech) hybridized with full-length ^{32}P -labelled human cDNA encoding for ERAB polypeptide. Controls were performed by hybridizing the same blots with ^{32}P -labelled cDNA for β -actin. **Fig. 3D.** Immunoblotting of brain extracts with anti-ERAB polypeptide IgG. Extracts of human brain temporal lobe were prepared as described (19) and subjected to SDS-PAGE (12%; reduced; 100 μg protein/lane) and immunoblotting. Blots were reacted with rabbit anti-ERAB polypeptide IgG (3 $\mu\text{g}/\text{ml}$) and sites of IgG binding were detected by the chemiluminescence method (Amersham®). In Fig. 3D, lanes 1-2 (designated AD) and Fig. 3D, lanes 3-4 (designated C), extracts were prepared from temporal lobes of two different AD and age-matched normal brains, respectively. Figure 3D lanes 5-6 show the same samples as in Fig. 3D lanes 1-2, but excess TrcHis-ERAB polypeptide fusion protein was present (20 $\mu\text{g}/\text{ml}$). **Figs. 3E, 3F-1 and 3F-2.** Immunostaining for ERAB polypeptide in age-matched normal (Fig. 3E) and AD (Fig. 3F) brain. Brains, obtained within 8 hrs of expiration of the patients, were fixed in paraformaldehyde (4%), paraffin-embedded, sectioned and stained with anti-ERAB polypeptide IgG (30 $\mu\text{g}/\text{ml}$). Fig. 3F-2 shows double staining displaying amyloid-beta peptide (black) (19) and ERAB polypeptide (red), and was performed as described (19). Scale bar: Figs. 3E and 3F-1 = 31 μm ; Fig. 3F-2 = 25 μm .

Figures 4A, 4B, 4C, 4D, 4E, 4F, 4G, 4H, and 4I. Expression of ERAB polypeptide in cultured cells: localization to the endoplasmic reticulum and change in distribution following addition of amyloid-beta peptide. Fig. 4A. Immunoblotting of ERAB polypeptide in human neuroblastoma SK-N-SH (Figure 4A, lane 1) and HeLa (Figure 4A, lane 2) cells. Cell extracts (50 μ g protein/lane) were subjected to immunoblotting using anti-ERAB polypeptide IgG (3 μ g/ml). Figs. 4B, 4C, and 4D. Confocal microscopy demonstrating immuno-fluorescence staining for ERAB polypeptide alone (Fig. 4B; red), protein disulfide isomerase alone (Fig. 4C; green), or simultaneous colocalization of these two antigens (Fig. 4D). Scale bar= 25 μ m. Fig. 4E. Subcellular fractionation of ERAB nucleic acid-transfected human neuroblastoma cells. Transfected cells (5×10^8) were pelleted and fractionated in a series of sucrose steps (38%, 30% and 20%) by ultracentrifugation (100,000 for 3 hrs). Layered (Fig. 4E lanes 1-4) and pelleted fractions (Fig. 4E lane 5) were subjected to Western blotting using either anti-ERAB polypeptide IgG (upper panel) or anti-GRP78 IgG (lower panel). Lanes correspond to cytosol (Fig. 4E lane 1), plasma membrane (Fig. 4E lane 2), Golgi apparatus (Fig. 4E lane 3), and endoplasmic reticulum (Fig. 4E lanes 4-5). Figs. 4F and 4G. Effect of exogenous amyloid-beta peptide(1-42) on ERAB polypeptide distribution. Neuroblastoma cells were incubated in buffer alone or in the presence of amyloid-beta peptide(1-42; 1 μ M), and the distribution of ERAB polypeptide was determined by immunofluorescence with anti-ERAB polypeptide IgG. The antigen becomes localized in packet apparently apposed to plasma membrane. Scale bars E= 31 μ m and F= 34 μ m. Figs. 4H and 4I. Co-immunoprecipitation of ERAB polypeptide and amyloid-beta peptide. Neuroblastoma cells (2×10^7) were incubated with 125 I-amyloid-beta peptide (100 nM) for 6 hrs at 37°C, unbound tracer was removed by extensive washing followed by dissolution of cells in lysis buffer (19). Immunoprecipitation was performed with anti-ERAB polypeptide IgG (10 μ g/ml; lane 2) or nonimmune IgG (10 μ g/ml; lane 1),

and samples were subjected to tris-tricine gel electrophoresis (Fig. 4I). Alternatively, neuroblastoma cells (2×10^7) were incubated with ^{125}I -amyloid-beta peptide (100 nM) for 6 hrs at 37°C , disuccinimidyl suberate (DSS; 0.2 mM; Pierce) was added for 30 min at 25°C , cells were washed extensively to remove free ^{125}I -amyloid-beta peptide and nonreacted DSS, followed by dissolution of cells in lysis buffer and processing of samples as above (samples were run on nonreduced SDS-PAGE, 10%). In lane 1, immunoprecipitation was performed with nonimmune IgG and in lane 2 anti-ERAB polypeptide IgG was employed. Methods: For indirect immunofluorescence, cells were plated on coverslips, fixed in formaldehyde (3.7%) for 15 min, and permeabilized in Triton X-100 (0.5%) for 5 min. For co-staining, coverslips were sequentially incubated for periods of 1-1.5 hrs at room temperature with monoclonal anti-protein disulfide isomerase (StressGen), anti-mouse FITC (Pierce), rabbit anti-ERAB polypeptide IgG and anti-rabbit TRITC IgG (Pierce). Samples were visualized on a Leica TCS confocal microscope. For subcellular fractionation studies, human neuroblastoma cells were transfected with pcDNA3-ERAB polypeptide encoding vector using the lipofectamine method (19), and fractionated as described following freeze thawing, nitrogen cavitation, homogenization and ultracentrifugation (63).

Figures 5A, 5B, 5C, 5D, 5E, and 5F. ERAB polypeptide contributes to amyloid-beta peptide-induced cellular toxicity in ERAB nucleic acid-transfected COS cells. Fig. 5A. Immunoblotting of mock-transfected (Fig. 54 lane 1) or ERAB nucleic acid-transfected COS cells (Fig. 5A lane 2; in each case 50 μg protein/lane was loaded) using anti-ERAB polypeptide IgG (3 $\mu\text{g}/\text{ml}$). Protein extracts were subjected to SDS-PAGE (12%; reduced) followed by immunoblotting as described above. Fig. 5B. ERAB nucleic acid-transfected COS cells displayed enhanced suppression of MTT reduction in the presence of amyloid-beta peptide. COS cells were transiently transfected with the pcDNA3-ERAB vector or

pcDNA3 alone, and, 24 hrs later (at which time ERAB polypeptide is expressed at high levels), amyloid-beta peptide (2 μ M) was added for 24 hrs at 37°C. Then, MTT reduction was determined (36); the mean \pm SEM of six replicate determinations is shown. * indicates $p < 0.05$. Figs. 5C, 5D, 5E, and 5F. COS cells were transfected with either vector alone (Fig. 5C), pcDNA3-ERAB vector (Fig. 5D) or pcDNA3-amyloid-beta peptide(1-42; Fig. 5E), or were co-transfected with pcDNA3-ERAB vector and pcDNA3-amyloid-beta peptide(1-42) vectors (Fig. 5F). Overexpression of ERAB polypeptide and/or amyloid-beta peptide was observed in each case, and cultures were photographed at that time. Marker bar= 138 μ m. Methods: Transfection was achieved using pcDNA3 vectors bearing either the cDNA for ERAB polypeptide and/or amyloid-beta peptide (A4 corresponding to residues 1-42) using lipofectamine according to the manufacturer's instructions. Maximal cellular expression of ERAB polypeptide and amyloid-beta peptide was observed 24-72 hrs later. MTT reduction was performed and photomicrographs obtained as described (19,36).

Figures 6A, 6B, 6C, 6D, 6E, 6F, and 6G. ERAB polypeptide contributes to amyloid-beta peptide-induced cytotoxicity in neuroblastoma cells. A-B. Introduction of anti-ERAB polypeptide and nonimmune F(ab')₂ into neuroblastoma cells (SK-N-SH). F(ab')₂ fragments derived from either anti-ERAB polypeptide IgG (Fig. 6A; prepared according to the manufacturer's instructions; Pierce) or nonimmune IgG (Fig. 6B; 13 μ g in each case) were introduced into neuroblastoma cells using lipofectamine as described (65). Immunostaining demonstrates cellular association of the F(ab')₂ fragments in each case. Scale bar = 18 μ m. Fig. 6C. Effect of anti-ERAB polypeptide F(ab')₂ on amyloid-beta peptide-induced suppression of MTT reduction. Anti-ERAB polypeptide or nonimmune F(ab')₂ was introduced into SK-N-SH cells as above, and, 24 hrs later, cultures were incubated with the indicated concentrations of amyloid-beta peptide for 20 hrs at 37°C. The mean \pm SEM of six replicates is shown. *

indicates $p < 0.05$. Figs. 6D, 6E, 6F, and 6G. Effect of anti-ERAB polypeptide $F(ab')_2$ on amyloid-beta peptide-induced morphologic changes. Anti-ERAB polypeptide or nonimmune $F(ab')_2$ was introduced into SK-N-SH cells, cultures were incubated with amyloid-beta peptide (1-42; $1 \mu M$), and were then photographed: Fig. 6D, untreated cultures; Fig. 6E, cultures exposed to amyloid-beta peptide; Fig. 6F, cultures into which anti-ERAB polypeptide $F(ab')_2$ was introduced using liposomes then exposed to amyloid-beta peptide; and Fig. 6G, cultures into which nonimmune $F(ab')_2$ was introduced using liposomes then exposed to amyloid-beta peptide. Scale bar = $138 \mu m$.

Figure 7. Overexpression of a mutant form of beta-amyloid precursor protein (βAPP) which causes increased expression of amyloid-beta protein (βA), and ERAB causes increased toxicity (DNA fragmentation) to COS cells.

Detailed Description

As used herein, a polypeptide is an amino acid polymer of amino acids linked together by peptide bonds; a nucleic acid
5 is a deoxyribonucleotide or ribonucleotide polymer of nucleotides linked together by phosphodiester bonds; an antisense nucleic acid is a nucleic acid that is the reverse complement of another nucleic acid which may be capable of inhibiting transcription or translation of the other nucleic
10 acid; a vector is a nucleic acid that can self replicate; a host cell is a cell containing a vector; an antibody is a protein with a specific affinity for an antigen; an antibody binding fragment (F(ab)) is a portion of an antibody which binds to the antigen; and a transgenic animal is an animal
15 whose cells comprise a foreign nucleic acid or naturally occurring nucleic acid in unnatural quantities or frequency (84).

As used herein, the term "ERAB" is an abbreviation for
20 "endoplasmic reticulum associated amyloid-beta peptide binding." The term "ERAB polypeptide" refers to an endoplasmic reticulum associated amyloid-beta binding polypeptide. ERAB polypeptide has a biological activity characterized by the capability of binding to amyloid-beta
25 peptide. ERAB polypeptide is also characterized by hydroxysteroid dehydrogenase activity. The term "ERAB nucleic acid" refers to a nucleic acid encoding ERAB polypeptide. The term "ERAB antisense nucleic acid" refers to the noncoding nucleic acid corresponding to an ERAB
30 nucleic acid. The term "ERAB antibody" refers to an antibody to the antigen "ERAB polypeptide." The term "ERAB antibody F(ab)" refers to the antigen binding fragment of an ERAB antibody.

35 This invention provides an ERAB polypeptide. In an embodiment, the ERAB polypeptide has a theoretical weight of about 27,000 daltons. In another embodiment, the ERAB polypeptide has an SDS-PAGE-determined weight of about

29,000 daltons. One embodiment of an ERAB polypeptide is human ERAB polypeptide or a murine ERAB polypeptide. In a specific embodiment a human ERAB polypeptide has the amino acid sequence shown in Figure 1D (Seq. Id. No. 2). Another
5 embodiment may be a portion of the ERAB polypeptide amino acid sequence shown in Figure 1D (Seq. Id. No. 2).

The present invention includes variants of ERAB polypeptide which encompass proteins and peptides with amino acid
10 sequences having seventy percent or eighty percent homology with the amino acid sequence shown in Figure 1D (Seq. Id. No. 2) or a naturally occurring ERAB polypeptide. More preferably the sequence homology is at least ninety percent, or at least ninety-five percent.

15 Variants in amino acid sequence of ERAB polypeptide are produced when one or more amino acids in naturally occurring ERAB polypeptide is substituted with a different natural amino acid, an amino acid derivative, a synthetic amino
20 acid, an amino acid analog or a non-native amino acid. Particularly preferred variants include homologous ERAB polypeptide of humans or of different species of animals. Variants of an ERAB polypeptide may include biologically active fragments of naturally occurring ERAB polypeptide,
25 wherein sequences of the variant differ from the wild type ERAB polypeptide sequence by one or more conservative amino acid substitutions. Such substitutions typically would have minimal influence on the secondary structure and hydrophobic nature of the ERAB polypeptide. Variants may
30 also have sequences which differ by one or more non-conservative amino acid substitutions, deletions or insertions which do not abolish the biological activity associated with ERAB polypeptide. Conservative substitutions (substituents) typically include the
35 substitution of one amino acid for another with similar characteristics such as substitutions within the following groups: valine, glycine; glycine, alanine; valine, isoleucine; aspartic acid, glutamic acid; asparagine,

glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. The non-polar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

Other conservative substitutions are exemplified Table 1, and yet others are described by Dayhoff in the Atlas of Protein Sequence and Structure (1988) (86).

Table 1: Conservative Amino Acid Replacements

For Amino Acid	Code	Replace with any of
Alanine	A	D-Ala, Gly, beta-ALA, L-Cys, D-Cys
Arginine	R	D-Arg, Lys, homo-Arg, D-homo-Arg, Met, D-Met, Ile, D-Ile, Orn, D-Orn
Asparagine	N	D-Asn, Asp, D-Asp, Glu, D-Glu, Gln, D-Gln
Aspartic Acid	D	D-Asp, D-Asn, Asn, Glu, D-Glu, Gln, D-Gln
Cysteine	C	D-Cys, S-Me-Cys, Met, D-Met, Thr, D-Thr
Glutamine	Q	D-Gln, Asn, D-Asn, Glu, D-Glu, Asp, D-Asp
Glutamic Acid	E	D-Glu, D-Asp, Asp, Asn, D-Asn, Gln, D-Gln
Glycine	G	Ala, D-Ala, Pro, D-Pro, Beta-Ala, Acp
Isoleucine	I	D-Ile, Val, D-Val, Leu, D-Leu, Met, D-Met

Leucine	L	D-Leu, Val, D-Val, Met, D-Met
Lysine	K	D-Lys, Arg, D-Arg, homo-Arg, D-homo-Arg, Met, D-Met, Ile, D-Ile, Orn, D-Orn
Methionine	M	D-Met, S-Me-Cys, Ile, D-Ile, Leu, D-Leu, Val, D-Val, Norleu
Phenylalanine	F	D-Phe, Tyr, D-Thr, L-Dopa, His, D-His, Trp, D-Trp, Trans 3,4 or 5-phenylproline, cis 3,4 or 5 phenylproline
Proline	P	D-Pro, L-I-thioazolidine-4-carboxylic acid, D- or L-1-oxazolidine-4-carboxylic acid
Serine	S	D-Ser, Thr, D-Thr, allo-Thr, Met, D-Met, Met(O), D-Met(O), Val, D-Val
Threonine	T	D-Thr, Ser, D-Ser, allo-Thr, Met, D-Met, Met(O) D-Met(O), Val, D-Val
Tyrosine	Y	D-Tyr, Phe, D-Phe, L-Dopa, His, D-His
Valine	V	D-Val, Leu, D-Leu, Ile, D-Ile, Met, D-Met

Other variants within the invention are those with modifications which increase peptide stability. Such variants may contain, for example, one or more non-peptide bonds (which replace the peptide bonds) in the peptide sequence. Also included are: variants that include residues other than naturally occurring L-amino acids, such as D-amino acids or non-naturally occurring or synthetic amino acids such as beta or gamma amino acids. Incorporation of D- instead of L-amino acids into the polypeptide may increase its resistance to proteases. See, e.g., U.S. Patent 5,219,990 (87).

An ERAB polypeptide variant of this invention includes an ERAB polypeptide varied by changes such as insertions, deletions and substitutions, either conservative or nonconservative where such changes might provide for certain advantages in their use such as increased potency, bioavailability, stability or decreased toxicity or degradation under physiological conditions.

In other embodiments, variants with amino acid substitutions which are less conservative may also result in desired derivatives of ERAB polypeptide, e.g., by causing desirable changes in charge, conformation and other biological properties. Such substitutions would include for example, substitution of hydrophilic residue for a hydrophobic residue, substitution of a cysteine or proline for another residue, substitution of a residue having a small side chain for a residue having a bulky side chain or substitution of a residue having a net positive charge for a residue having a net negative charge. When the result of a given substitution cannot be predicted with certainty, the derivatives may be readily assayed according to the methods disclosed herein to determine the presence or absence of the desired characteristics.

Just as it is possible to replace substituents of the scaffold (i.e., amino acids which make up the ERAB polypeptide), it is also possible to substitute functional groups which decorate the scaffold with groups characterized by similar features (i.e., R-groups which are part of each amino acid). These substitutions will initially be conservative, i.e., the replacement group will have approximately the same size, shape, hydrophobicity and charge as the original group. Non-sequence modifications may include, for example, in vivo or in vitro chemical derivatization of portions of naturally occurring ERAB polypeptide, as well as changes in acetylation, methylation, phosphorylation, carboxylation or glycosylation.

In a further embodiment the ERAB polypeptide is modified by chemical modifications in which activity is preserved. For example, the ERAB polypeptide may be amidated, sulfated, singly or multiply halogenated, alkylated, carboxylated, or phosphorylated. The ERAB polypeptide may also be singly or multiply acylated, such as with an acetyl group, with a farnesyl moiety, or with a fatty acid, which may be saturated, monounsaturated or polyunsaturated. The fatty acid may also be singly or multiply fluorinated. The invention also includes methionine analogs of ERAB polypeptide, for example the methionine sulfone and methionine sulfoxide analogs. The invention also includes salts of ERAB polypeptide, such as ammonium salts, including alkyl or aryl ammonium salts, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogen phosphate, thiosulfate, carbonate, bicarbonate, benzoate, sulfonate, thiosulfonate, mesylate, ethyl sulfonate and benzensulfonate salts.

Variants of ERAB polypeptide may also include peptidomimetic compounds of ERAB polypeptide. Such compounds are well known to those of skill in the art and are produced through the substitution of certain R groups or amino acids in the protein with non-natural replacements. Such substitutions may increase the stability, bioavailability, or activity of such ERAB polypeptide compound.

The present invention provides an ERAB nucleic acid. One embodiment of an ERAB nucleic acid is a recombinant ERAB nucleic acid. A further embodiment of an ERAB nucleic acid is human ERAB nucleic acid. An embodiment of an ERAB nucleic acid is an ERAB deoxyribonucleic acid (DNA), a recombinant nucleic acid, or an ERAB ribonucleic acid. A specific embodiment of human ERAB nucleic acid is a cDNA sequence which corresponds to the sequence shown in Figure 1D from nucleotide 19 to nucleotide 801 or a portion thereof. One embodiment of the present invention is murine ERAB nucleic acid.

The invention also provides variants of the ERAB nucleic acid. Variants of ERAB nucleic acid may include nucleic acid sequences having seventy percent or eighty percent homology with the ERAB nucleic acid sequence shown in Figure 1D. More preferably the sequence homology is at least ninety percent, or at least ninety-five percent. Variants of ERAB nucleic acid may include alleles of ERAB nucleic acid, truncated ERAB nucleic acid, alternatively spliced ERAB nucleic acid, ERAB nucleic acid with silent mutations or conservative mutations. A variant of ERAB nucleic acid may also include portions of naturally occurring ERAB nucleic acid or ERAB nucleic acid with deletions of some regions of the nucleic acid.

The present invention provides an ERAB antisense nucleic acid. In one embodiment, the ERAB antisense nucleic acid is human ERAB antisense nucleic acid or a portion of human ERAB antisense nucleic acid. In a further embodiment, the human ERAB antisense nucleic acid sequence in the 3' to 5' direction corresponds to the nucleic acid sequence shown in Figure 1D in the 5' to 3' direction.

The antisense nucleic acid may be capable of inhibiting translation or transcription of an ERAB nucleic acid or an mRNA derived from an ERAB nucleic acid. The antisense sequence to ERAB nucleic acid may be linked to a replicable vector. The ERAB antisense nucleic acid may be administered to a subject in order to treat a neurodegenerative condition. The ERAB antisense nucleic acid may inhibit the binding of an ERAB polypeptide in a cell to amyloid-beta peptide.

The present invention provides for a replicable vector containing an ERAB nucleic acid or a variant thereof. In one embodiment the vector is a prokaryotic expression vector, a yeast expression vector, a baculovirus expression, a mammalian expression vector, an episomal mammalian expression vector, pKK233-2, pEUK-C1, pREP4, pBlueBacHis A,

pYES2, pSE280, or pEBVHis. Methods for the using these replicable vectors may be found in Sambrook et al., 1989, (79) or Kriegler, 1990, (88).

5 The present invention provides for an host cells comprising an ERAB nucleic acid or variant thereof. In one embodiment the host cell is a eukaryotic cell, a somatic cell, a germ cell, a neuronal cell, a myocyte, a prokaryotic cell, a virus packaging cell, or a stem cell.

10

This invention provides the production of biologically active ERAB polypeptide in a prokaryotic expression system, a eukaryotic expression system, a mammalian expression system, a baculovirus expression system, an insect expression system or a yeast expression system. This production may provide for the post-translational modifications which exist in naturally occurring ERAB polypeptide. For protocols describing bacterial expression of mammalian proteins, see Sambrook et al, 1989 (79).

15

20

The present invention provides a transgenic animal whose cells express ERAB nucleic acid or a variant thereof. In one embodiment, the cells of the transgenic animal contain human ERAB nucleic acid. In another embodiment the transgenic animal is a non-human mammal. In another embodiment, the non-human mammal is a mouse, monkey, a dog, a swine, a fowl or a rat. In a specific embodiment, the transgenic animal may be a non-human mammal whose germ and somatic cells contain a human ERAB nucleic acid, the nucleic acid having been stably introduced into the non-human mammal at the single cell stage or an embryonic stage, and wherein the nucleic acid is linked to a promoter and integrated into the genome of the non-human mammal. The transgenic animal may be a descendant of an animal containing cells which have been transfected with ERAB nucleic acid or a variant thereof.

25

30

35

The present invention provides an antibody which is an antibody or a portion thereof which specifically binds to an ERAB polypeptide or variant thereof. In one embodiment the antibody is a polyclonal antibody, a monoclonal antibody or an antigen binding fragment (F(ab)) of antibody. In another embodiment, the antibody comprises an antibody which binds to human ERAB polypeptide or to murine ERAB polypeptide or to a portion of the polypeptide shown in Figure 1D.

One of ordinary skill in the art would know how to make and use such an antibody. The present invention provides for a fragment of an antibody to ERAB polypeptide, namely [F(ab')₂] which is capable of blocking the binding activity of ERAB polypeptide to amyloid-beta peptide. Such antibodies may be introduced into cells and may be capable of suppressing the toxicity or cell stress due to amyloid-beta peptide. The antibody may be a small synthetic peptide. The antibody may block the binding of ERAB polypeptide to amyloid-beta peptide by binding to a binding site on an ERAB polypeptide or on an amyloid-beta peptide.

The present invention provides a method to determine the ability of an agent to inhibit binding of ERAB polypeptide to amyloid-beta peptide which comprises: (a) incubating ERAB polypeptide and the agent with amyloid-beta peptide; (b) determining the amount of amyloid-beta peptide bound to ERAB polypeptide; and (c) comparing the determined amount with an amount determined when the agent is absent, thereby determining the ability of the agent to inhibit the binding of ERAB polypeptide to amyloid-beta peptide. The agent may be a peptide, a peptidomimetic compound, a nucleic acid, or a small molecule. In one embodiment, the agent may be marked with a reporter molecule. In another embodiment, the ERAB polypeptide or amyloid-beta peptide may be marked with a reporter molecule.

A "reporter molecule", as defined herein, is a molecule or atom which, by its chemical nature, provides an identifiable

signal allowing detection of the level of production of a particular protein, mRNA or transcript. Detection can be either qualitative or quantitative. The present invention provides for the use of any commonly used reporter molecule including radionucleotides, enzymes, biotins, psoralens, fluorophores, chelated heavy metals, and luciferase. The most commonly used reporter molecules are either enzymes, fluorophores, or radionucleotides linked to the nucleotides which are used in transcription. Commonly used enzymes include horseradish peroxidase, alkaline phosphatase, glucose oxidase and α -galactosidase, β -glucuronidase among others. The substrates to be used with the specific enzymes are generally chosen because a detectably colored product is formed by the enzyme acting upon the substrate. For example, p-nitrophenyl phosphate is suitable for use with alkaline phosphatase conjugates; for horseradish peroxidase, 1,2-phenylenediamine, 5-aminosalicylic acid or toluidine are commonly used. The probes so generated have utility in the detection of a specific ERAB nucleic acid target in, for example, Southern analysis, Northern analysis, *in situ* hybridization to tissue sections or chromosomal squashes and other analytical and diagnostic procedures. The methods of using such hybridization probes are well known and some examples of such methodology are provided by Sambrook et al, 1989 (79). The reporter molecule may be linked to a probe for an ERAB nucleic acid or an ERAB antibody and may be used for prognosis determination in a subject for neurodegenerative conditions.

An example of a model agent which would inhibit the binding of ERAB polypeptide to amyloid-beta peptide includes an $F(ab')_2$ prepared from anti-ERAB polypeptide-derived IgG, IgM, IgE or any other immunoglobulin molecule. The $F(ab')_2$ fragment of the antibody may be used instead of the whole IgG molecule since it is to be introduced into a cell and the whole antibody would likely have nonspecific effects due to its Fc region. The agent described herein may work when it is introduced into cells. Such introduction may be

achieved via liposomes, Lipofectin, calcium precipitation and other methods. Such methods of introducing compounds, protein, nucleic acid and polypeptides into cells are well known to one of ordinary skill in the art.

5

The present invention also provides assays for the determination or identification of compounds capable of inhibiting the binding of ERAB polypeptide to amyloid-beta peptide. Such an assay may include the binding of radiolabelled ¹²⁵I-amyloid-beta peptide or labelled amyloid-beta peptide of any form to ERAB polypeptide. The amyloid-beta peptide or the ERAB polypeptide may be bound to a solid support. The amyloid-beta peptide or the ERAB polypeptide may be a fusion protein. The assay may also detect the binding of amyloid-beta peptide to immobilized ERAB polypeptide. Compounds may be added to the reaction mixture and detection of binding or the inhibition of binding may be determined. Such assays are useful for the identification of compounds which could be used as agents capable of inhibiting the binding of the amyloid-beta peptide with ERAB polypeptide. Such an agent may be used as a drug or a pharmaceutical composition or a preventative drug to ameliorate, prevent, treat or improve neurodegenerative conditions in subjects. The subjects may be humans, animals, mice, dogs, cats or other animals. Such animals may be useful human model systems.

The present invention provides a method to determine the prognosis of a neurodegenerative condition in a subject which comprises: (a) obtaining a sample from the subject; (b) contacting the sample with a reagent capable of binding to an element in the sample, the element comprising ERAB nucleic acid or ERAB polypeptide or variant thereof, under conditions such that the reagent binds only if the element is present in the sample; and (c) detecting the presence of the reagent bound to the element and thereby determining the prognosis of the neurodegenerative condition of the subject.

In an embodiment of this invention the subject is a mammal. Examples of suitable mammalian subjects include, but are not limited to, murine animals such as mice and rats, hamsters, rabbits, goats, pigs, sheep, cats, dogs, cows, monkeys and humans.

The present invention further provides a method to treat or cure a neurodegenerative condition in a subject which comprises administering to the subject a pharmaceutically acceptable composition, such composition comprising an agent capable of inhibiting the interaction or binding of ERAB polypeptide with amyloid-beta peptide in the subject, in an amount effective to treat or cure the neurodegenerative condition in the subject.

The agent or compound determined or identified by the above assays or methods may be used as a drug or in a pharmaceutical composition. Such drug or pharmaceutical composition may be administered to subjects suffering from a neurodegenerative condition. The administration times, concentrations, and duration would be known by one of ordinary skill in the art and would depend on a number of discernable factors including the body weight of the subject, the type of the neurodegenerative condition, the stage of the condition, the age of the subject, the health of the subject, among other factors.

The present invention provides a pharmaceutical composition which comprises an agent capable of inhibiting binding of amyloid-beta peptide to ERAB polypeptide and a pharmaceutically acceptable carrier thereof. The carrier may be a diluent, an aerosol, a topical carrier, an aqueous solution, a nonaqueous solution or a solid carrier.

In the practice of any of the methods of the invention or preparation of any of the pharmaceutical compositions, a "therapeutically effective amount" is an amount which is effective to alter the binding of ERAB polypeptide to

amyloid-beta peptide and thus treat the neurodegenerative condition of the subject. Accordingly, the effective amount will vary with the subject being treated, as well as the condition to be treated. For the purposes of this invention, the methods of administration are to include, but are not limited to, administration cutaneously, subcutaneously, intravenously, parenterally, orally, topically, or by aerosol.

As used herein, the term "suitable pharmaceutically acceptable carrier" encompasses any of the standard pharmaceutically accepted carriers, such as phosphate buffered saline solution, water, emulsions such as an oil/water emulsion or a triglyceride emulsion, various types of wetting agents, tablets, coated tablets and capsules. An example of an acceptable triglyceride emulsion useful in intravenous and intraperitoneal administration of the compounds is the triglyceride emulsion commercially known as Intralipid®.

Typically such carriers contain excipients such as starch, milk, sugar, certain types of clay, gelatin, stearic acid, talc, vegetable fats or oils, gums, glycols, or other known excipients. Such carriers may also include flavor and color additives or other ingredients.

By means of well-known techniques such as titration and by taking into account the observed pharmacokinetic characteristics of the agent in the individual subject, one of skill in the art can determine an appropriate dosing regimen (85).

The present invention further provides for a method for treating a neurodegenerative condition in a subject which comprises administering to the subject an amount of an agent effective to inhibit ERAB binding to amyloid-beta peptide thereby treating the neurodegenerative condition.

The neurodegenerative condition may comprise Alzheimer's disease, Down's syndrome, Parkinson's disease, Huntington's disease, schizophrenia, multiple sclerosis, senility, stroke, demyelinating disease, or a heritable condition.

5

As used herein, the term "neurotoxicity" encompasses the negative metabolic, biochemical and physiological effects on a neuronal cell which may result in a debilitation of the neuronal cellular functions. Such functions may include memory, learning, perception, neuronal electrophysiology (ie. action potentials, polarizations and synapses), synapse formation, both chemical and electrical, channel functions, neurotransmitter release and detection and neuromotor functions. Neurotoxicity may include neuronal cytotoxicity.

15

As used herein, the term "neuronal degeneration" encompasses a decline in normal functioning of a neuronal cell. Such a decline may include a decline in memory, learning, perception, neuronal electrophysiology (ie. action potentials, polarizations and synapses), synapse formation, both chemical and electrical, channel functions, neurotransmitter release and detection and neuromotor functions. In the present invention, the subject may be a mammal or a human subject. The administration may be intralesional, intraperitoneal, intramuscular or intravenous injection; infusion; liposome-mediated delivery; gene bombardment; topical, nasal, oral, anal, ocular or otic delivery.

25

The present invention provides for a pharmaceutical composition which comprises an antibody specific for ERAB polypeptide and a pharmaceutically acceptable carrier thereof. The present invention also provides for a pharmaceutical composition which comprises an antisense nucleic acid corresponding to ERAB nucleic acid or a variant thereof and a pharmaceutically acceptable carrier thereof. The present invention provides for a pharmaceutical composition which comprises a portion of an ERAB polypeptide

30

35

sufficient to inhibit binding of ERAB polypeptide to amyloid-beta peptide in a cell and a pharmaceutically acceptable carrier.

5 Also provided by the invention are pharmaceutical compositions comprising therapeutically effective amounts of products of the invention together with suitable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers. A "therapeutically effective amount" as used
10 herein refers to that amount which provides a therapeutic effect for a given condition and administration regimen. [One example would be a sufficient amount to treat or ameliorate a neurodegenerative condition in a subject, such as Alzheimer's Disease.] Such compositions are liquids or
15 lyophilized or otherwise dried formulations and include diluents of various buffer content (e.g., Tris-HCl., acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile
20 acid salts), solubilizing agents (e.g., glycerol, polyethylene glycerol), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (e.g., lactose, mannitol), covalent attachment of
25 polymers such as polyethylene glycol to the protein, complexation with metal ions, or incorporation of the material into or onto particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, hydrogels, etc, or onto liposomes, microemulsions, micelles,
30 unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts. Such compositions will influence the physical state, solubility, stability, rate of *in vivo* release, and rate of *in vivo* clearance. The choice of compositions will depend on the physical and chemical
35 properties of the exact protein or compound having the activity of inhibiting the neurodegenerative condition. For example, a product derived from a membrane-bound form of a protein may require a formulation containing detergent.

Controlled or sustained release compositions include formulation in lipophilic depots (e.g., fatty acids, waxes, oils). Also comprehended by the invention are particulate compositions coated with polymers (e.g., poloxamers or poloxamines) and the compound coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to ligands of tissue-specific receptors. Other embodiments of the compositions of the invention incorporate particulate forms protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal, oral, injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial or intralesional.

Another embodiment of this invention is a method for evaluating the ability of an agent to inhibit binding of an amyloid-beta peptide with an ERAB polypeptide in a cell which includes: a) contacting the cell with the agent; b) determining the amount of amyloid-beta peptide bound to ERAB polypeptide in the cell; and c) comparing the amount of bound amyloid-beta peptide to ERAB polypeptide determined in step b) with the amount determined in the absence of the agent, thus evaluating the ability of the agent to inhibit the binding of amyloid-beta peptide to ERAB polypeptide in the cell.

The agent may be capable of specifically binding to the amyloid-beta peptide or to ERAB polypeptide. The agent may bind to amyloid-beta peptide at the site where ERAB polypeptide interacts. The agent may be a soluble portion of an ERAB polypeptide which is not associated with a cell membrane. The agent may be bound to a solid support. The agent may be expressed on the surface of a cell or may be produced inside of the cell.

Portions of the compound of the invention may be "labeled" by association with a detectable marker substance (e.g.,

radiolabeled with ^{125}I or biotinylated) to provide reagents useful in detecting and quantifying the presence of ERAB polypeptide or ERAB nucleic acid or their derivatives in solid tissue and fluid samples such as blood, cerebral spinal fluid or urine.

When administered, agents are often cleared rapidly from the circulation and may therefore elicit relatively short-lived pharmacological activity. Consequently, frequent injections of relatively large doses of bioactive agents may be required to sustain therapeutic efficacy. Agents modified by the covalent attachment of water-soluble polymers such as polyethylene glycol, copolymers of polyethylene glycol and polypropylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone or polyproline are known to exhibit substantially longer half-lives in blood following intravenous injection than do the corresponding unmodified agents (80, 82, 83). Such modifications may also increase the agent's solubility in aqueous solution, eliminate aggregation, enhance the physical and chemical stability of the agent, and greatly reduce the immunogenicity and reactivity of the agent. As a result, the desired *in vivo* biological activity may be achieved by the administration of such polymer-agent adducts less frequently or in lower doses than with the unmodified agent.

Attachment of polyethylene glycol (PEG) to agents or compounds is particularly useful because PEG has very low toxicity in mammals (81). For example, a PEG adduct of adenosine deaminase was approved in the United States for use in humans for the treatment of severe combined immunodeficiency syndrome. A second advantage afforded by the conjugation of PEG is that of effectively reducing the immunogenicity and antigenicity of heterologous compounds. For example, a PEG adduct of a human protein might be useful for the treatment of disease in other mammalian species without the risk of triggering a severe immune response. The agent may be delivered in a microencapsulation device so

as to reduce or prevent an host immune response against the agent or against cells which may produce the agent. The agent of the present invention may also be delivered microencapsulated in a membrane, such as a liposome.

5

Polymers such as PEG may be conveniently attached to one or more reactive amino acid residues in a protein such as the alpha-amino group of the amino terminal amino acid, the epsilon amino groups of lysine side chains, the sulfhydryl groups of cysteine side chains, the carboxyl groups of aspartyl and glutamyl side chains, the alpha-carboxyl group of the carboxy-terminal amino acid, tyrosine side chains, or to activated derivatives of glycosyl chains attached to certain asparagine, serine or threonine residues.

15

Numerous activated forms of PEG suitable for direct reaction with proteins have been described. Useful PEG reagents for reaction with protein amino groups include active esters of carboxylic acid or carbonate derivatives, particularly those in which the leaving groups are N-hydroxysuccinimide, p-nitrophenol, imidazole or 1-hydroxy-2-nitrobenzene-4-sulfonate. PEG derivatives containing maleimido or haloacetyl groups are useful reagents for the modification of protein free sulfhydryl groups. Likewise, PEG reagents containing amino hydrazine or hydrazide groups are useful for reaction with aldehydes generated by periodate oxidation of carbohydrate groups in proteins.

20

25

The present invention incorporates U.S. Patent Nos. 5,446,128, 5,422,426 and 5,440,013 in their entireties as references which disclose the synthesis of peptidomimetic compounds and methods related thereto. The compounds of the present invention may be synthesized using these methods.

30

In addition to the agents disclosed herein having naturally-occurring amino acids with peptide or unnatural linkages, the present invention also provides for other structurally similar compounds or agents such as polypeptide analogs with

35

unnatural amino acids in the compound. Such compounds may be readily synthesized on a peptide synthesizer available from vendors such as Applied Biosystems, Dupont and Millipore.

5

The present invention provides for a method for treating a subject suffering from a neurodegenerative condition which comprises administering to the subject a compound capable of inhibiting binding of ERAB polypeptide to amyloid-beta peptide in the subject and thereby treating the subject suffering from a neurodegenerative condition. This present invention encompasses gene therapy, especially for patients with acute neurodegenerative conditions.

15

There are several protocols for human gene therapy which have been approved for use by the Recombinant DNA Advisory Committee (RAC) which conform to a general protocol of target cell infection and administration of transfected cells (66, 69, 70). In addition, U.S. Patent No. 5,399,346 (Anderson, W. F. et al., issued March 21, 1995) describes procedures for retroviral gene transfer (68). The contents of these support references are incorporated in their entirety into the subject application. Retroviral-mediated gene transfer requires target cells which are undergoing cell division in order to achieve stable integration hence, cells are collected from a subject often by removing blood or bone marrow. It may also be possible to remove cerebrospinal fluid or brain tissue. It may be necessary to select for a particular subpopulation of the originally harvested cells for use in the infection protocol. For example, white blood cells may be separated from red blood cells using an apheresis procedure. The white cells may then be placed in culture with mitogens, such as IL-2 or OKT3 (which can stimulate T-cell proliferation) for approximately 18 hrs. Then, a retroviral vector containing the gene(s) of interest would be mixed into the culture medium. The vector binds to the surface of the subject's cells, enters the cells and inserts the gene of interest

20

25

30

35

randomly into a chromosome. The gene of interest is now stably integrated and will remain in place and be passed to all of the daughter cells as the cells grow in number. The cells may be expanded in culture for a total of 9-10 days before reinfusion (69, 70). As the length of time the target cells are left in culture increases, the possibility of contamination also increases, therefore a shorter protocol would be more beneficial.

One skilled in the art would recognize that retroviruses, adenoviruses, parvoviruses, and herpes viruses have been used to transfer genes (77).

The present invention also includes a compound which is capable of inhibiting the enzymatic activity of ERAB polypeptide. The compound may inhibit or alter the synergistic effect of amyloid-beta peptide on ERAB polypeptide. The compound may prevent the interaction of ERAB polypeptide with amyloid-beta peptide thereby altering the enzymatic activity of ERAB polypeptide and thus improving a neurodegenerative condition.

Another embodiment of the present invention is a method for alleviating symptoms of a neurodegenerative condition in a subject which includes administering to the subject a compound described hereinabove, the compound being present in an amount effective to inhibit neuronal cell death and thus alleviate the symptoms of the neurodegenerative condition in the subject.

The neurodegenerative condition may be associated with aging, Alzheimer's disease, dentatorubral and pallidolysian atrophy, Huntington's disease, Machado-Joseph disease, multiple sclerosis, muscular dystrophy, Parkinson's disease, senility, spinocerebellar ataxia type I, spinobulbar muscular atrophy, stroke, trauma. The subject may be a mammal. The mammal may be a human. The administration may include aerosol delivery; intralesional, intraperitoneal,

intramuscular or intravenous injection; infusion; liposome-mediated delivery; anal, nasal, oral, ocular, otic or topical delivery of the pharmaceutical composition.

5 In one embodiment, the condition may be associated with degeneration of a neuronal cell in the subject, with formation of an amyloid-beta peptide fibril, with aggregation of amyloid-beta peptide, with infiltration of a microglial cell into a senile plaque, or with activation of
10 a microglial cell by an amyloid-beta peptide, wherein the activation comprises production of cytokines by the microglial cell.

15 This invention is illustrated in the Experimental Details section which follows. These sections are set forth to aid in an understanding of the invention but are not intended to, and should not be construed to, limit in any way the invention as set forth in the claims which follow thereafter.

20

Experimental Details

Example 1: ERAB Polypeptide - A Novel Intracellular amyloid-beta peptide Binding Polypeptide Which Mediates Neurotoxicity In Alzheimer's Disease

Amyloid-beta peptide is neurotoxic and is implicated in the pathogenesis of Alzheimer's disease(1-6). Using the yeast two-hybrid system, a novel endoplasmic reticulum-associated amyloid-beta binding polypeptide (ERAB polypeptide), putatively identified as a hydroxysteroid dehydrogenase, was shown to be expressed in normal tissues and, at higher levels, in affected neurons in the brain in Alzheimer's disease. ERAB polypeptide, constitutively produced by neuroblastoma cells was co-immunoprecipitated with amyloid-beta peptide; following exposure of cultures to exogenous amyloid-beta peptide, ERAB polypeptide was rapidly redistributed to the inner aspect of the plasma membrane. Toxicity of amyloid-beta peptide to neuroblastoma cells was prevented by liposome-mediated introduction of anti-ERAB polypeptide F(ab')₂ antibody into the cell and was enhanced by overexpression of ERAB polypeptide in COS cells. These data implicate a novel intracellular binding protein, ERAB polypeptide, as an integral participant in amyloid-beta-cellular interactions, and suggest a mechanism whereby amyloid-beta peptide could gain access to cellular compartments containing ERAB polypeptide. There may be other cell surface molecules capable of tethering amyloid-beta peptide, as indicated by the incomplete blockade of amyloid-beta peptide-cell surface interaction by preventing access to RAGE, and the characterization of other molecules which also bind amyloid-beta peptide, such as the type I macrophage scavenger receptor present on microglia (20-21).

Another potentially important mechanism of cytotoxicity of amyloid-beta peptide species could result from their engagement by intracellular targets. Intracellular

accumulation of amyloidogenic amyloid-beta peptide has been observed in several cell types(22-27); this could reflect aberrant cellular processing with excessive amounts of amyloid-beta peptide (≈ 4 kDa) generated within the cell, or from uptake of amyloid-beta peptide released into the medium. In addition, larger C-terminal fragments of APP might in themselves exert neurotoxic effects. These data led to consideration of the possibility that amyloid-beta peptide and amyloid-beta peptide-containing polypeptides might act at specific intracellular sites relevant to the neurotoxicity underlying AD. Using the yeast two-hybrid system(28-29), an intracellular amyloid-beta peptide binding protein in the endoplasmic reticulum which mediates, at least in part, the ability of amyloid-beta peptide to induce cellular toxicity was identified. These data provide the first direct evidence for an intracellular binding site for amyloid-beta peptide, and indicate that intracellular amyloid-beta peptide, in addition to amyloid-beta peptide in the extracellular space, can exert deleterious effects on cellular functions.

Identification and cloning of ERAB.

The yeast two-hybrid system was used to screen human brain and HeLa cell Matchmaker™ cDNA libraries for encoded proteins capable of binding to the fusion protein containing amyloid- β -peptide. In order to screen the libraries, the portion of human amyloid precursor protein sequence encoding amyloid-beta peptide was subcloned into the yeast expression vector pGBT9 containing the GAL4 DNA-binding domain (Fig. 1A). Out of 3×10^6 clones screened from each library, one positive clone was identified from human brain and three positive clones from HeLa cells. By DNA sequencing, all four clones (designated as ERAB, see below) gave the same cDNA sequence, except for minor variations at the 5'-end cloning site. Strong β -galactosidase activity was observed when constructs containing nucleic acid encoding amyloid-beta peptide(1-42 and 3-42) and ERAB polypeptide were co-

expressed (Figs. 1B and 1C). The specificity of ERAB polypeptide interaction with amyloid-beta peptide in this system was further demonstrated by lack of β -galactosidase activity when the amyloid-beta peptide-related construct or the ERAB nucleic acid construct was replaced with vector-only constructs (Figs. 1B and 1C). The construct pGBT/APP-23, which contained β -amyloid precursor protein (APP)-derived amino acids 655-751 (encoding a peptide starting at residue 3 in amyloid-beta peptide and extending for 95 amino acids towards the C-terminus), showed no β -galactosidase activity, indicating that the C-terminus of APP prevents amyloid-beta peptide interaction with ERAB polypeptide, suggesting that normally expressed APP is not a ligand for ERAB polypeptide. Using the 5'-rapid amplification of cDNA ends (RACE), the 5'-end of a human ERAB nucleic acid was cloned; the sequence was found to extend about 18 bp upstream of the first AUG and the start codon of the open reading frame was consistent with Kozak consensus sequences(30). The full-length cDNA sequence coded for a predicted 262 amino acid polypeptide (Fig. 1D, Seq. Id. Nos. 1 and 2). Comparison with the SWISS-PROT and Protein Data Bank databases, using the FASTA algorithm(31-32), showed amino acid sequences of ERAB polypeptide to most closely resemble the family of short-chain alcohol dehydrogenases, including hydroxysteroid dehydrogenases, Ke6, and acetoacetyl-CoA reductases(33-34). In both cases, ERAB polypeptide exhibited an identity score of 32% and a similarity score of 65%. Alignment of ERAB polypeptide with the 255 amino acids of the nicotinamide adenine dinucleotide (NAD) binding enzyme 3 α ,20 β -hydroxysteroid dehydrogenase (EC1.1.1.53) of *Streptomyces hydrogenans*, for which the X-ray structure at 2.6Å resolution is available(34), revealed a series of common structural motifs (Figs. 1E-1 and 1E-2, ERAB as Seq. Id. No. 3 and 2 BHD as Seq. Id. No. 4); both share the NAD(H) binding domains, as well as the highly conserved sequence YGASK in the bacterial enzyme (residues 152-165), which in the human ERAB polypeptide corresponds to

residues 168-172 (YSASK), putatively assigned as part of the active center of the enzyme.

To study the ability of ERAB polypeptide to bind amyloid-beta peptide, TrcHis-ERAB fusion protein was expressed in *E. coli* and purified. Immunoblotting with polyclonal antibodies prepared by immunizing an animal with ERAB polypeptide-derived peptides, to produce an anti-ERAB IgG antibody, indicated the presence of the target ERAB polypeptide sequence in the fusion protein, but not in the control fusion protein, TrcHis-chloramphenicol acetyltransferase (CAT) (Fig. 2A; lanes 1-2). The specificity of anti-ERAB polypeptide IgG antibody was shown by its recognition of the TrcHis-ERAB fusion protein when the latter was present in crude cell lysates, and disappearance of this band on addition of excess free ERAB polypeptide-derived peptide identical to that used as immunogen (Fig. 2A, lane 3). Purified TrcHis-ERAB adsorbed to microtiter wells bound ^{125}I -amyloid-beta peptide (synthetic 1-40) dependent on the amount of immobilized ERAB polypeptide (Fig. 2B), and this was blocked by antibody to ERAB polypeptide but not by nonimmune IgG (Fig. 2C). No specific binding of ^{125}I -amyloid-beta peptide was observed to wells coated with albumin (Fig. 2B, bar designated "0") or TrcHis-CAT. At one concentration of immobilized TrcHis-ERAB polypeptide, binding of ^{125}I -amyloid-beta peptide was saturable with $K_d = 51.6 \pm 15.7 \text{ nM}$ (Fig. 2D). The specificity of freshly prepared ^{125}I -amyloid-beta peptide (1-40) binding to TrcHis-ERAB polypeptide was shown by competition experiments in which excess unlabelled freshly prepared synthetic amyloid-beta peptide (1-40), synthetic amyloid-beta peptide (1-40) incubated for 3 days at 37°C (under conditions promoting aggregation) (6), synthetic amyloid-beta peptide (1-20), and AD-derived amyloid-beta peptide (mainly 1-42) blocked binding, but synthetic amyloid-beta peptide (25-35), scrambled amyloid-beta peptide (25-35), and Arg-Gly-Asp-Ser (Seq. ID. No. 5) had no effect (Fig. 2E). Experiments in which TrcHis-ERAB

polypeptide was radioiodinated and amyloid-beta peptide(1-42) was adsorbed to microtiter wells also showed similar specific binding dependent on the concentration of amyloid-beta peptide (Fig. 2F). Complementary studies in which a single concentration of amyloid-beta peptide(1-42) was immobilized on wells and varying amounts of ^{125}I -TrcHis-ERAB were added showed dose-dependent binding with $K_d = 88.3 \pm 28.1$ nM (Fig. 2G). In contrast, excess unlabelled TrcHis-CAT did not inhibit the binding of ^{125}I -TrcHis-ERAB to microtiter wells with adsorbed amyloid-beta peptide. These data demonstrate that ERAB polypeptide and amyloid-beta peptide interact specifically in the nanomolar range.

Tissue and cellular localization of ERAB

ERAB mRNA was expressed ubiquitously in normal human tissues and brain subregions as a single transcript of ≈ 1 kb in each case (Figs. 3A, 3B, and 3C); the highest levels of ERAB transcripts were in liver and heart, but ERAB nucleic acid was also expressed elsewhere, including normal brain. ERAB antigen, detected with anti-ERAB derived polyclonal antibody, was visualized on SDS-PAGE as a ≈ 29 kDa band in extracts of normal brain from two individuals (Fig. 3D, lanes 3-4). This apparent molecular weight is close to that predicted from analysis of the ERAB polypeptide sequence (26925.7 Daltons). Intensity of the band observed on immunoblots with AD brain from two different patients (Fig. 3D, lanes 1-2) was greater than that observed in brain extracts from age-matched controls (Fig. 3D, lanes 3-4; a total of five AD and three controls were analyzed). The immunoreactive band in AD brain was blocked by addition of excess free TrcHis-ERAB (Fig. 3D, lanes 5-6), but not by free TrcHis-CAT. Immunostaining of normal brain showed ERAB polypeptide to be predominately localized in neurons (Fig. 3E); controls with nonimmune IgG or with anti-ERAB IgG in the presence of excess ERAB peptide were unstained. Increased neuronal ERAB polypeptide expression was observed in AD brain (Fig. 3F-1), especially near deposits of

amyloid-beta peptide (Fig. 3F-2). These histologic results are representative of seven AD brains and five age-matched normal brains, the postmortem times of which were <8 hrs.

5 Histologic evidence and the apparent absence of a signal peptide or transmembrane spanning domain indicated that ERAB polypeptide was intracellular. Immunoblotting demonstrated expression of ERAB polypeptide as a single ≈ 29 kDa band in both human neuroblastoma (SK-N-SH; Fig. 4A, lane 1) and HeLa cells (Fig. 4A, lane 2) whose appearance was blocked by excess free TrcHis-ERAB. Confocal microscopy of HeLa cultures showed ERAB polypeptide to be distributed (Fig. 4B) identically with the endoplasmic reticulum marker protein disulfide isomerase(35) (Fig. 4C), as shown in double immunofluorescence images for both antigens (Fig. 4D). Similar results were obtained with neuroblastoma cells and ERAB-transfected COS cells. In neuroblastoma cells transfected to overexpress ERAB polypeptide, subcellular fractionation showed ERAB antigen in fractions containing the endoplasmic reticulum marker GRP78 (Fig. 4E, lanes 4-5), but not in fractions containing plasma membrane, cytosol, or Golgi (Fig. 4E, lanes 1-3). Based on immunostaining with ERAB IgG and on binding studies with labelled anti-ERAB IgG, ERAB polypeptide was not identified on the cell surface. Furthermore, in studies using markers for mitochondria, lysosomes and Golgi complex, ERAB polypeptide was not found in these compartments. These data suggested that ERAB polypeptide was only present in the endoplasmic reticulum.

30 These observations also posed an apparent paradox, for, how could amyloid-beta peptide, most of which is extracellular, interact with a polypeptide associated with endoplasmic reticulum? First, it was observed that the presence of amyloid-beta peptide influenced the distribution of ERAB polypeptide; addition of amyloid-beta peptide(1-42) to neuroblastoma cells resulted in a marked change in the cellular localization of ERAB polypeptide from its original intracellular sites (Fig. 4F) to granular-particulate

accumulations of apparently associated with the inner aspect of the cell membrane (Fig. 4G; no ERAB polypeptide was detected in nonpermeabilized cells). These changes were specific for amyloid-beta peptide, as neither scrambled amyloid-beta peptide nor an unrelated peptide (Arg-Gly-Asp-Ser) (Seq. ID. No. 5) similarly perturbed the distribution of ERAB polypeptide. Second, it was determined that ERAB polypeptide became associated with amyloid-beta peptide, and that amyloid-beta peptide-induced effects on ERAB polypeptide were not likely mediated by an indirect mechanism. To demonstrate this, SK-N-SH cells were incubated with ^{125}I -amyloid-beta peptide(1-40), and immunoprecipitation of cell-associated peptide was performed using antibodies to ERAB. From cell lysates, anti-ERAB IgG precipitated ^{125}I -labelled ≈ 4 kDa molecule visualized on tris-tricine gels which corresponded to amyloid-beta peptide (Fig. 4H, lane 2), whereas nonimmune IgG did not precipitate any bands (Fig. 4H, lane 1). To confirm that ERAB polypeptide and amyloid-beta peptide interacted in intact cultured cells, neuroblastoma cells were incubated for 6 hrs at 37°C with ^{125}I -amyloid-beta peptide followed by addition of the crosslinker disuccinimidyl suberate (Fig. 4I). Cultures were then washed extensively, to remove unbound tracer and unreacted crosslinker, followed by lysis of the cells and immunoprecipitation with anti-ERAB IgG or nonimmune IgG. Antibody to ERAB polypeptide precipitated a ^{125}I -labelled band with $\text{Mr} \approx 38$ kDa (Fig. 4I, lane 2), most likely corresponding to a complex of ERAB polypeptide with an oligomer (dimer-trimer) of ^{125}I -amyloid-beta peptide; in contrast, no bands were precipitated with nonimmune IgG (Fig. 4I, lane 1). These data show that amyloid-beta peptide directly affects the cellular distribution of ERAB polypeptide, and that ERAB polypeptide-amyloid-beta peptide interaction occurs in intact cells.

ERAB polypeptide contributes to amyloid-beta peptide-mediated cellular toxicity.

Elucidating the role of ERAB polypeptide in amyloid-beta peptide-induced cellular stress was critical to evaluating its functional significance. Following transfection, COS-1 cells overexpressed ERAB polypeptide (Fig. 5A, lane 2), compared with mock-transfected cultures (Fig. 5A, lane 1). Exposure to amyloid-beta peptide of cultures overexpressing ERAB polypeptide suppressed their capacity to reduce 3-(4,5-dimethylthiazol-2-yl)-2,5, diphenyl tetrazolium bromide (MTT) (36), as compared with mock-transfected controls (Fig. 5B). COS cells were then transfected with vectors causing overexpression of either ERAB polypeptide, amyloid-beta peptide or both ERAB polypeptide and amyloid-beta peptide. In cells transfected with the plasmid causing overexpression of amyloid-beta peptide there were increased levels of amyloid-beta peptide, both cell-associated peptide and that released into the medium, which reached a maximum after 24 hrs. Cells transfected with pcDNA3-ERAB nucleic acid showed increased expression of ERAB polypeptide which was only cell-associated. Cytotoxicity was especially evident in COS cells cotransfected with vectors causing overexpression of both ERAB polypeptide and amyloid-beta peptide: compared with COS-1 transfected with vector alone (Fig. 5C), or those overexpressing only ERAB polypeptide (Fig. 5D) or amyloid-beta peptide (Fig. 5E), cells from cultures cotransfected with both ERAB nucleic acid and amyloid-beta peptide appeared shrunken and clumped (Fig. 5F).

The effect of ERAB nucleic acid and protein expression on sensitivity of neuroblastoma cells (which normally express ERAB polypeptide) to amyloid-beta peptide-induced stress was studied using blocking $F(ab')_2$ prepared from anti-ERAB IgG. For these studies, anti-ERAB or nonimmune $F(ab')_2$ was introduced into neuroblastoma cells using lipofectamine. In each case, the $F(ab')_2$ fragments became cell-associated (Fig. 6A-B). After liposome-mediated introduction of the $F(ab')_2$,

SK-N-SH cultures were incubated with a range of amyloid-beta peptide concentrations; whereas cultures exposed to nonimmune-derived F(ab')₂ showed marked amyloid-beta peptide-induced suppression of MTT reduction (comparable to untreated controls, anti-ERAB-derived F(ab')₂ protected against amyloid-beta peptide-induced suppression of MTT reduction (Fig. 6C). In contrast, addition of anti-ERAB F(ab')₂ directly to the medium (i.e., not in liposomes) had no affect on amyloid-beta peptide-induced MTT suppression, consistent with the intracellular localization of ERAB polypeptide. Parallelling the protective effect of blocking ERAB polypeptide intracellularly, introduction of anti-ERAB F(ab')₂ into SK-N-SH cells using liposomes suppressed amyloid-beta peptide-induced changes in cellular morphology. Control SK-N-SH cultures display typical short neurites and an extended cell body (Fig. 6D); but, after exposure to amyloid-beta peptide, retraction of neurites and rounding up of cell bodies was observed (Fig. 6E). Introduction of anti-ERAB F(ab')₂ into SK-N-SH cells prevented, in large part, these amyloid-beta peptide-induced morphologic changes (Fig. 6F), whereas F(ab')₂ derived from nonimmune IgG had no effect (Fig. 6G).

DISCUSSION

Neurotoxicity in Alzheimer's disease may result from a concatenation of factors, such as: (1) enhanced cellular processing of APP, releasing amyloidogenic amyloid-beta peptide peptides; (2) interaction of amyloid-beta peptide with cell membranes, both at specific cell binding sites and, presumably, by direct actions on the membrane itself; (3) nonenzymatic glycation of macromolecules whose turnover is delayed in AD brain, producing modified structures which can form crosslinks and generate reactive oxygen intermediates; and, (4) cellular components that comprise the protective response to oxidant stress and/or increase susceptibility to apoptotic stimuli(1-6,15,16,36-40). Mutant presenilins, associated with most familial forms of Alzheimer's disease(11-12)and present in endoplasmic

reticulum and Golgi complex(41), provide an instructive example of this multifactorial pathogenesis. Increased production of amyloid-beta peptide occurs in transgenic mice overexpressing mutant presenilins, and in the plasma and cultured fibroblasts from carriers of familial AD linked to chromosome 1(42-44). In addition, presenilin 2, which is homologous to ALG-3, a protein involved in programmed cell death, can function as a susceptibility factor for apoptosis in differentiated PC12 cells, in response to growth factor/serum withdrawal or to addition of amyloid-beta peptide(45).

ERAB polypeptide adds a new dimension to the pathogenetic interaction of amyloid-beta peptide with cellular elements. Like presenilin 2(45), ERAB polypeptide also appears to potentiate cellular perturbations due to amyloid-beta peptide. However, the true physiologic roles of both ERAB polypeptide and presenilins remain unknown. Addition of amyloid-beta peptide to COS cells overexpressing ERAB polypeptide caused more exaggerated suppression of MTT reduction, and greater retraction of the cells than that induced by the peptide alone. Similarly, in neuroblastoma cells, which constitutively express ERAB polypeptide, amyloid-beta peptide-induced impairment of MTT reduction and of cell morphology were suppressed by introduction of anti-ERAB F(ab')₂. Therefor it was proposed that ERAB polypeptide may contribute to AD pathology as a progression factor, enhancing cellular stress due to increased levels of amyloid-beta peptide. Although the mechanism through which ERAB polypeptide promotes amyloid-beta peptide-mediated changes in cellular functions is not clear, ERAB polypeptide and amyloid-beta peptide appear to interact in intact cells. First, addition of amyloid-beta peptide to cells expressing ERAB polypeptide changes its intracellular distribution. Second, COS cells, transfected to overexpress ERAB polypeptide and then exposed to exogenous ¹²⁵I-amyloid-beta peptide, formed immunoprecipitable ERAB - ¹²⁵I-amyloid-beta peptide complexes. Radioligand binding studies indicated

the specificity of ERAB-amyloid-beta peptide interaction, but it is not yet known whether ERAB polypeptide binds preferentially to monomer, oligomer, or fibrillar forms of amyloid-beta peptide. A cross-linking study with ¹²⁵I-amyloid-beta peptide-ERAB polypeptide strongly suggests that a soluble, probably dimer or small oligomer of amyloid-beta peptide(46-47) can serve as a ligand for ERAB polypeptide.

Analysis of the ERAB nucleic acid and protein sequence has suggested that ERAB polypeptide might be a part of the cellular enzymatic machinery, possibly functioning as a hydroxysteroid dehydrogenase. The interaction of amyloid-beta peptide with such an intracellular polypeptide is certainly not something that would have been predicted. However, there may be an analogy in binding of glyceraldehyde-3-phosphate dehydrogenase to the expanded polyglutamine repeats coded for by the CAG triplet(48) in mutant forms of the Huntington protein(49), and in other polypeptides associated with other neurodegenerative conditions(49-52). There may be an effect of amyloid-beta peptide on the enzymatic activity of ERAB polypeptide. But, how can amyloid-beta peptide gain access to this intracellular polypeptide which is apparently confined to the endoplasmic reticulum? After addition of amyloid-beta peptide to neuroblastoma cultures expressing ERAB polypeptide, it still cannot be detected on the cell surface. Thus, in order for ERAB polypeptide to interact with amyloid-beta peptide, the amyloidogenic peptide must gain access to the proper intracellular compartment. In this context, although some past studies have demonstrated amyloid-beta peptide aggregates and amyloid fibrils within cells(53-59). Such deposits, however, are usually localized to an endosomal-lysosomal compartment. The association of amyloid-beta peptide with intracellular neurofibrillary tangles has also been noted, suggesting that some amyloid-beta peptide gains access to the cytosolic milieu (it would be difficult to visualize the free ERAB peptide unless it

becomes associated to a morphologically identifiable structure, such as a neurofibrillary tangle or an amyloid fibril). Potentially, following endocytosis, amyloid-beta peptide could be diverted from the endosomal-lysosomal compartment, where it is also generated(1-6), at least in part, and gain access to the endoplasmic reticulum by a pathway yet to be defined. Alternatively, based on the location of cleavage sites in APP which produce amyloid-beta peptide, including one within the transmembrane spanning domain(1-6), another possible mechanism might be release of peptide to both intra- and extra-cellular spaces.

ERAB transcripts are apparently widely distributed in the body, with highest expression in normal liver and heart. It is possible that ERAB polypeptide participates in homeostatic cellular functions. By virtue of its localization in the endoplasmic reticulum, it may usually function in cellular metabolism, perhaps as a dehydrogenase in steroid biogenesis. ERAB polypeptide may modulate cellular function in normal and perturbed cells.

Example 2: ERAB is critical for ERAB potentiation of amyloid-beta cytotoxicity. The following data indicates that an inhibitor of ERAB activity could provide a therapy to protect neurons from Alzheimer's disease.

A mutant of ERAB was created in which tyrosine (169) and lysine (173) were replaced by glycine. These two residues, tyrosine and lysine, are essential components of the active site of ERAB which is an enzyme. The mutant ERAB was expressed and characterized as follows: (1) its immunoblotting showed the same molecular weight (about 27,000 Da) as the native ERAB which is expected for the small change introduced by the mutation, (2) the mutant form is devoid of enzyme activity because enzyme assays for ERAB activity as an NAD-dependent short chain alcohol dehydrogenase (octanol as the substrate) showed no activity and the mutant ERAB did showed no activity towards 17-beta-

estradiol (whereas native ERAB is an hydroxysteroid dehydrogenase) or towards S-acetoacetyl-Coenzyme A (whereas native ERAB is an hydroxyacyl Coenzyme A dehydrogenase), (3) when cells were transfected with the mutant ERAB with mutant amyloid-beta precursor protein which produces more amyloid-beta peptide, no increased toxicity to the cell was observed which contrasts with the increased apoptosis, as measured by ELISA for cytoplasmic histone-associated DNA fragments, caused by the cotransfection of wild-type ERAB with mutant amyloid-beta precursor protein.

These findings indicate that an inhibitor of ERAB could protect neurons from the toxic effects of amyloid-beta peptide.

Figure 7 shows that expression of a mutant form of beta-amyloid precursor protein (β APP), which causes increased expression of amyloid-beta protein ($A\beta$) and ERAB causes increased toxicity (DNA fragmentation) to COS cells.

Experimental Procedure:

COS cells were grown in cell culture and transfected using lipofectamine procedure with the following DNA constructs:

1. Wild-type ERAB.

2. Mutant ERAB. This was made by site-directed mutagenesis resulting in replacement of tyrosine [169] and lysine [173] with glycine (at 169 and 173). Mutant ERAB results in the expression of a protein of molecular weight \approx 27 kDa which has no enzymatic activity compared with native wild-type ERAB. Native or wild-type ERAB has three distinct enzymatic activities which were assayed: (a) short chain alcohol dehydrogenase (octanol as the substrate); (b) β -hydroxyacyl-Coenzyme A dehydrogenase (S-acetoacetyl-Coenzyme A as substrate); and (c) hydroxysteroid dehydrogenase (17- β -estradiol as the substrate).

3. Mutant β APP. This was derived from the London mutation of β APP in which valine at position 717 is replaced by

glycine. A reference describing a plasmid which can be used to express this molecule is Wild-Bode, C., et al. (1997) Intracellular generation and accumulation of amyloid β -peptide termination at amino acid 42. J. Biol. Chem. 272:16085-16088.

The assay for cell toxicity was measurement of DNA fragmentation by determining cytoplasmic histone-associated DNA fragments (one could use Cell Death ELISA from Boehringer-Mannheim®).

Experimental Protocol:

Cells were transfected with either wild type ERAB alone, mutant β APP alone, mutant ERAB alone or lipofectamine alone. Lipofectamine is the lipid to make the vesicles for transfection and serves as a negative control. Cells were cotransfected with either wild type ERAB and mutant β APP (see Figure 7; wt-ERAB/mut-APP) or mutant ERAB and mutant APP (see Figure 7; mut-ERAB/mut-APP).

Cells were allowed to incubate for 24 hours at 37°C, and then the cell death ELISA assay was performed.

Results:

Increased DNA fragmentation, consistent with the occurrence of apoptosis (programmed cell death) occurred in cells cotransfected with wild type ERAB and mutant β APP. This did not occur when cells were transfected with either wild type ERAB or mutant β APP alone. In contrast, cells cotransfected with mutant ERAB and mutant β APP did NOT show increased DNA fragmentation. Expression of mutant ERAB and mutant β APP was confirmed by Western blotting, thus the proteins are expressed but apoptosis did not occur.

Thus, the enzymatically inactivated ERAB does not promote the toxicity of $A\beta$ in the same manner as wild type $A\beta$. Note that mutant β APP produces increased amounts of $A\beta$ and causes cytotoxicity which is enhanced by ERAB.

References

1. Haass, C., & Selkoe, D. Cell 7:1039-1042 (1994).
2. Kosik, K. J. Cell Biol. 127:1501-1504 (1994).
- 5 3. Yankner, B. et al. Science 245:417-420 (1989).
4. Scheuner, D. et al. Nature Med. 2:864-869 (1996).
5. Roses, A. Nature Med. 2:267-269 (1996).
6. Cai, X. et al. Science 259:514-516 (1993).
7. Citron, M. et al. Nature 360:672-674 (1992).
- 10 8. Hendriks, L. et al. Nature Genet. 1:218-222 (1992).
9. Mullan, M. et al. Nature Genet. 1:345-347 (1992).
10. Haass, C. et al. J. Biol. Chem. 269:17741-17748 (1994).
11. Sherrington, R. et al. Nature 375:754-760 (1993).
- 15 12. Citron, M. et al. Nature Med. 3:67-72 (1997).
13. Levy-Lahad, E. et al. Science 269:970-972 (1995).
14. Hensley, K. et al. Proc. Natl. Acad. Sci. (USA) 91:3270-3274 (1994).
15. Mattson, M. and Goodman, Y. Brain Res. 676:219-224 (1995).
- 20 16. Mattson, M. Neurobiol. Aging 16:661-674 (1995).
17. Yankner, B. et al. Science 250:279-282 (1990).
18. Boland, K. et al. J. Biol. Chem. 271:18032-18044 (1996).
- 25 19. Yan, S-D. et al. Nature 382:685-691 (1996).
20. Paresce, D. et al. Neuron 17:553-565 (1996).
21. El-Khoury, J. et al. Nature 382:716-719 (1996).
22. Yoshikawa, K. et al. Nature 359:64-67 (1992).
23. Fukuchi, K. et al. Biochem. Biophys. Res. Commun. 182:165-173 (1992).
- 30 24. Martin, B. et al. J. Biol. Chem. 270:26727-26730 (1995).
25. Fuller, S. et al. Biochemistry 34:8091-8098 (1995).
26. Matsumoto, A. Biochim. Biophys. Acta 1225:304-310 (1994).
- 35 27. Frackowiak, J. et al. Brain. Res. 676:225-230 (1995).
28. Fields, S. and Song, O-K. Nature 340:245-246 (1991).
29. Chien, C-T. et al. PNAS(USA) 88:9578-9582 (1991).

30. Kozak, M. Nucleic Acids Res. 15:8125-8131 (1987).
31. Bernstein, F. et al. J. Mol. Biol. 112:535-542 (1977).
32. Devereux, J. et al. Nucleic Acids. Res. 12:387-395 (1984).
- 5 33. Ghosh, D. et al. PNAS(USA) 88:10064-10068 (1991).
34. Schembri, M. et al. J. Bacteriol. 177:4501-4507 (1995).
35. Edman, J. et al. Nature 317:267-270 (1985).
36. Behl, C. et al. Cell 77:817-827 (1994).
- 10 37. Busciglio, J. and Yankner, B. Nature 378:776-779 (1995).
38. Vitek, M. et al. PNAS(USA) 91:4766-4770 (1994).
39. Yan, S-D. et al. PNAS(USA) 91:7787-7791 (1994).
- 15 40. Ledesma, M. et al. J. Biol. Chem. 269:21614-2169 (1994).
41. Kovacs, D. et al. Nature Med. 2:224-229 (1996).
42. Duff, K. et al. Nature 383:710-713 (1996).
43. Borchelt, D. et al. Neuron 17:1005-1013 (1996).
44. Scheuner, D. et al. Nature Med. 2:864-869 (1996).
- 20 45. Wlozozin, B. et al. Science 274:1710-1713 (1996).
46. Kuo, Y-M. et al. J. Biol. Chem. 271:4077-4081 (1996).
47. Roher, A. et al. J. Biol. Chem. 271:20631-20635 (1996).
48. Burke, J. R. et al. Nature Med. 2:347-350 (1996).
- 25 49. Huntington's Disease Collaborative Research Group Cell 72:971-983 (1993).
50. Koide, R. et al. Nature Genet. 6:9-13 (1994).
51. Nagafushi, S. et al. Nature Genet. 6:14-18 (1994).
52. Willems, P. Nature Genet. 8:213-215 (1994).
- 30 53. Knauer, M. et al. PNAS(USA) 89:7437-7441 (1992).
54. Perry, G. et al. Am. J. Pathol. 140:283-290 (1992).
55. Scott, R., et al. J. Biol. Chem. 271:8966-8970 (1996).
56. Fuller, S. et al. Biochem. 34:8091-8098 (1995).
57. Perry, G. et al. Am. J. Pathol. 143:1586-1593 (1993).
- 35 58. Yang, A. et al. J. Biol. Chem. 270:14786-14792 (1995).
59. Martin, B. et al. J. Biol. Chem. 270:26727-26730 (1995).

60. Klotz, I. and Hunston, D. J. Biol. Chem. 258:11442-11445 (1984).
61. Roher, A. et al. J. Biol. Chem. 268:3072-3083 (1993).
- 5 62. David, G. and Reisfeld, R. Biochem. 13:1014-1029 (1974).
63. Kuwabara, K. et al. J. Biol. Chem. 271:5025-5032 (1996).
64. Adelman, M. et al. Cell Biol. 56:191-205 (1973).
65. Yan, S-D. et al. Nature Med. 1:693-699 (1995).
- 10 66. Anderson, W.F. (1992) Human Gene Therapy. Science 256:808-813.
67. Anderson W.F. et al. (1990) Human Gene Therapy 1(3):327-62.
68. Anderson, W. F. et al. Gene Therapy, U. S. Patent No. 5,399,346, March 21, 1995, filed March 30, 1994, U. S. Serial No. 220,175.
- 15 69. Culver, K.W. et al. (1991a) Lymphocyte Gene Therapy, Human Gene Therapy 2(2):107-9.
70. Culver K.W. et al. (1991b) Transplantation Proceedings (1 Pt 1):170-1.
- 20 71. Larrick J.W. and Burck K.L. (1991) Gene Therapy: Application of Molecular Biology, New York, Elsevier.
72. Miller A.D. (1990) Blood 76:(2):271-8.
73. Miller A.D. (1990) Retrovirus Packaging Cells, Human Gene Therapy 1(1):5-14.
- 25 74. Miller A.D. (1992) Human Gene Therapy Comes of Age. Nature 357:455-460.
75. Miller A.D. and Buttimore C. (1986) Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Molec. Cell Biol. 6:2895-2902.
- 30 76. Miller A.D. et al. (1991) Construction and properties of retrovirus packaging cells based on Gibbon Ape Leukemia Virus. J.Virol. 65:2220-2224.
- 35 77. Mulligan, R.C. (1993). The basic science of gene therapy. Science 260:926-932.
78. Rosenberg S.A. et al. (1990) Gene transfer into humans - immunotherapy of patients with advanced melanoma,

using tumor-infiltrating lymphocytes modified by retroviral gene transduction. New England Journal of Medicine 323:570-8.

- 5 79. Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed.
80. Abuchowski et al., In: "Enzymes as Drugs", Holcenberg et al., eds. Wiley-Interscience, New York, NY, 367-383 (1981).
- 10 81. Carpenter et al., *Toxicol. Appl. Pharmacol.*, 18:35-40 (1971).
82. Katre et al., Proc. Natl. Acad. Sci. USA 84:1487-1491 (1987).
83. Newmark et al., J. Appl. Biochem. 4:185-189 (1982).
84. Stryer, L. (1988) Biochemistry.
- 15 85. Benet, et al., "Clinical Pharmacokinetics" in ch. 1 (pp. 20-32) of Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edition, A.G. Gilman, et al. eds. (Pergamon, New York 1990).
- 20 86. Dayhoff. (1988) Atlas of Protein Sequence and Structure.
87. U.S. Patent 5,219,990.
88. Kriegler, M. (1990) Gene Transfer and Expression: A Laboratory Manual, Stockton Press, New York, New York.

What is claimed is:

1. A purified ERAB polypeptide.
2. The polypeptide of claim 1, wherein the polypeptide
5 comprises the amino acid sequence shown in Figure 1D
(Seq. Id. No. 2) or a variant thereof.
3. The polypeptide of claim 2, wherein the polypeptide
10 comprises a portion of the amino acid sequence shown in
Figure 1D (Seq. Id. No. 2) or a portion of a variant
thereof.
4. The polypeptide of claim 1, wherein the polypeptide is
human or murine.
5. The polypeptide of claim 1, wherein the polypeptide
15 comprises a molecular weight of about 27,000 to 29,000
daltons.
6. An isolated nucleic acid which encodes an ERAB
polypeptide.
7. The nucleic acid of claim 6, wherein the ERAB
polypeptide comprises human ERAB polypeptide.
8. The nucleic acid of claim 6, wherein the nucleic acid
20 comprises the nucleic acid sequence shown in Figure 1D
(Seq. Id. No. 1) from nucleotide 19 to nucleotide 801
or a variant thereof.
9. The nucleic acid of claim 6, wherein the nucleic acid
25 is DNA, RNA, or a recombinant nucleic acid.
10. A replicable vector comprising the nucleic acid of
claim 6.
11. The replicable vector of claim 10, wherein the vector
30 is a prokaryotic expression vector, a yeast expression
vector, a baculovirus expression vector, a mammalian
expression vector, an episomal mammalian expression
vector, pKK233-2, pEUK-C1, pREP4, pBlueBacHis A, pYES2,
pSE280, or pEBVHis.

12. A host cell comprising the vector of claim 10.
13. The host cell of claim 12, wherein the host cell is a eukaryotic cell, a somatic cell, a germ cell, a neuronal cell, a myocyte, a prokaryotic cell, a virus packaging cell, or a stem cell.
14. The nucleic acid of claim 6, wherein the nucleic acid comprises antisense oriented nucleic acid.
15. A cell comprising a foreign nucleic acid, which nucleic acid comprises at least a portion of the nucleic acid sequence shown in Figure 1D from nucleotide 19 to a nucleotide 801 or a variant thereof.
16. An antibody to the polypeptide of claim 1.
17. The antibody of claim 16, wherein the antibody is a polyclonal antibody, a fragment of an antibody, or a monoclonal antibody.
18. A transgenic non-human mammal whose germ and somatic cells contain and express a nucleic acid molecule encoding human ERAB polypeptide or a biologically active variant thereof, the nucleic acid molecule having been stably introduced into the non-human mammal at the single cell stage or an embryonic stage, and wherein the nucleic acid molecule is linked to a promoter and integrated into the genome of the non-human mammal.
19. The transgenic non-human mammal of claim 18, wherein the animal is selected from the group consisting of a mouse, a rat, a swine, a fowl, a dog, or a nonhuman primate.
20. A method for evaluating the ability of an agent to inhibit binding of ERAB polypeptide to amyloid-beta peptide which comprises:

(a) incubating ERAB polypeptide, the agent and amyloid-beta peptide under suitable binding conditions;

5 (b) determining the amount of amyloid-beta peptide bound to ERAB polypeptide from the incubate of (a); and

10 (c) comparing the amount of bound amyloid-beta peptide determined in step (b) with an amount of amyloid-beta peptide bound to ERAB polypeptide determined in the absence of the agent, thereby evaluating the ability of the agent to inhibit binding of ERAB polypeptide to amyloid-beta peptide.

15 21. The method of claim 21, wherein the agent comprises a peptide, a peptidomimetic compound, a nucleic acid, or a small molecule.

20 22. A pharmaceutical composition which comprises an agent capable of inhibiting an interaction between an amyloid-beta peptide and an ERAB polypeptide and a pharmaceutically acceptable carrier.

25 23. The pharmaceutical composition of claim 23, wherein the carrier is a diluent, an aerosol, a topical carrier, an aqueous solution, a nonaqueous solution or a solid carrier.

30 24. A method for treating a neurodegenerative condition in a subject which comprises administering to the subject an agent, capable of inhibiting binding of an ERAB polypeptide to an amyloid-beta peptide, in an amount effective to inhibit such binding and thereby treat the neurodegenerative condition in the subject.

35 25. The method of claim 25, wherein the neurodegenerative condition comprises Alzheimer's disease, Down's syndrome, Parkinson's disease, Huntington's disease,

schizophrenia, a demyelinating disease or multiple sclerosis.

INTRACELLULAR AMYLOID-BETA BINDING (ERAB) POLYPEPTIDE

5

Abstract of the Disclosure

10

15

The present invention provides an isolated nucleic acid encoding an endoplasmic reticulum associated amyloid-beta peptide binding (ERAB) polypeptide. The ERAB polypeptide may comprise human ERAB polypeptide. The present invention provides a purified ERAB polypeptide, as well as a method for treating a neurodegenerative condition in a subject which comprises administering to the subject an agent in amount effective to inhibit ERAB polypeptide binding to amyloid-beta peptide so as to thereby treat the neurodegenerative condition.

100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219
2220
2221
2222
2223
2224
2225
2226
2227
2228
2229
2230
2231
2232
2233
2234
2235
2236
2237
2238
2239
2240
2241
2242
224

FIG. 1A




FIG. 1B

pAB002 +pGBT/ AB-13
 pAB002 +pBA-6
 pAB002 +pGBT9
 pGAD424 +pGBT/ AB-13
 pGAD424 +pBA-6
 pGAD424 +cGUT9
 pGAD424 +pGAD3





FIG. 1C




FIG. 1D

GGAGTGGCCGGCGACAAG 18

ATG GCA GCA GCG TGT CGG AGC GTG AAG GGC CTG GTG GCG GTA ATA ACC 66
 M A A A C R S V K G L V A V I T
 GGA GGA GCC TCG GGC CTG GGC CTG GCC ACG GCG GAG CGA CTT GTG GGG 114
 G G A S G L G L A T A E R L V G
 CAG GGA GCC TCT GCT GTG CTT CTG GAC CTG CCC AAC TCG GGT GGG GAG 162
 O G A S A V L L D L P N S G G E
 GCC CAA GCC AAG AAF TTA GGA AAC AAC TGC GTT TTC GCC CCA GCC GAC 210
 A Q A K K L G N N C V F A P A D
 GTG ACC TCT GAG AAG GAT GTG CAA ACA GCT CTG GCT CTA GCA AAA GGA 258
 V T S E K D V Q T A L A L A K G
 AAG TTT GGC CGT GTG GAT GTA GCT GTC AAC TGT GCA GGC ATC GCG GTG 306
 K F G R V D V A V N C A G I A V
 GCT AGC AAG ACG TAC AAC TTA AAG AAG GGC CAG ACC CAT ACC TTG GAA 354
 A S K T Y N L K K G Q T H T L E
 GAC TTC CAG CGA GTT CTT GAT GTG AAT CTC ATG GGC ACC TTC AAT GTG 402
 D F Q R V L D V N L M G T F N V
 ATC CGC CTG GTG GCT GGT GAG ATG GGC CAG AAT GAA CCA GAC CAG GGA 450
 I R L V A G E M G O N E P D O G
 GGC CAA CGT GGG GTC ATC ATC AAC ACT GCC AGT GTG GCT GCC TTC GAG 498
 G Q R G V I I N T A S V A A F E
 GGT CAG GTT GGA CAA GCT GCA TAC TCT GCT TCC AAG GGG GGA ATA GTG 546
 G Q V G Q A A Y S A S K G G I V
 GGC ATG ACA CTG CCC ATT GCT CGG GAT CTG GCT CCC ATA GGT ATC CGG 594
 G M T L P I A R D L A P I G I R
 GTG ATG ACC ATT GCC CCA GGT CTG TTT GGC ACC CCA CTG CTG ACC AGC 642
 V M T I A P G L F G T P L L T S
 CTC CCA GAG AAA GTG TGC AAC TTC TTG GCC AGC CAA GTG CCC TTC CCT 690
 L P E K V C N F L A S Q V P F P
 AGC CGA CTG GGT GAC CCT GCT GAG TAT GCT CAC CTC GTA CAG GCC ATC 738
 S R L G D P A E Y A H L V Q A I
 ATC GAG AAC CCA TTC CTC AAT GGA GAG GTC ATC CGG CTG GAT GGG GCC 786
 I E N P F L N G E V I R L D G A
 ATT CGT ATG CAG CCT TGA AGGGAGAAGGCAGAGAAAAACACACGCTCCTCTGCCCTTCCTT 842
 I R M Q P
 TCCCTGGGGTACTACTCTCCAGCTTGGGAGGAAGCCCAGTAGCCATTTTGTAACCTGCCCTACCGT 912
 GCCCTCTGTGCCTAATAAAGTCTCTTTTTCTCACAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 978

[illegible]

	60	70	80	90	100
ERAB	AKKLGNNCVFAPADVTSE	EKDVQOTALAKGKFG	RDVAVNC	AGI	AVASKT
	: : : : .	: : : : .	: : : : .	: : : : .	
2BHD	ARELGDAARYOHLDTIE	EEDWQRVVAYAREEFG	SV DGLVNN	AGI	STGMFL

	110	120	130	140	150
ERAB	YNLKKGQTHLTLEDFORVL	DVNL	MGTFN	IRLV	AGEMGONEPDGGQGRGVI
2BHD	-----ETESVERFRKVV	DI	NLTGV	FIGMKT	VI PAM-----KDAGG--GSI
	100	110	120	130	

[illegible]

7/22

FIG. 2A







FIG. 2B**FIG. 2C**

FIG. 2D**FIG. 2E**

Unlabelled competitors






FIG. 2F**FIG. 2G**

11/22

FIG. 3A




FIG. 3B





FIG. 3C



SECRET 1034660

FIG. 3D





FIG. 3F-1

FIG. 3E

FIG. 3F-2



1	2
200--	
97.4--	
68--	
48--	
30--	
21.5--	

FIG. 4A

FIG. 4D

FIG. 4C




FIG. 4B

FIG. 4E




FIG. 4F





FIG. 4G



1 2



1 2




FIG. 5A




FIG. 5B




FIG. 5F

FIG. 5E

FIG. 5D

FIG. 5C




FIG. 6A

FIG. 6B



FIG. 6C



SECRET 40216500

FIG. 6G


FIG. 6F

FIG. 6E

FIG. 6D



FIG. 7



[illegible]

Applicants: David M. Stern and Shi Du Yan

Declaration and Power of Attorney

Page 2

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below:

<u>Provisional Application No.</u>	<u>Filing Date</u>	<u>Status</u>
None		

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States Application(s), or Section 365(c) of any PCT International Application(s) designating the United States listed below. Insofar as this application discloses and claims subject matter in addition to that disclosed in any such prior Application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56, which became available between the filing date(s) of such prior Application(s) and the national or PCT international filing date of this application:

<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status</u>
PCT/US98/04915	12 March 1998	Pending
08/815,225	12 March 1997	Pending

And I hereby appoint

John P. White (Reg. No. 28,678); Christopher C. Dunham (Reg. No. 22,031); Norman H. Zivin (Reg. No. 25,385); Jay H. Maioli (Reg. No. 27,213); William E. Pelton (Reg. No. 25,702); Robert D. Katz (Reg. No. 30,141); Peter J. Phillips (Reg. No. 29,691); Wendy E. Miller (Reg. No. 35,615); Richard S. Milner (Reg. No. 33,970); Albert Wai-Kit Chan (Reg. No. 36,479); Robert T. Maldonado (Reg. 38,232); Paul Teng (40,837); George M. MacDonald (Reg. No. 39,284); Richard F. Jaworski (Reg. No. 33,515); Elizabeth M. Wieckowski (Reg. No. 42,226); Pedro C. Fernandez (Reg. No. 41,741); and Gary J. Gershik (Reg. No. 39,992).

and each of them, all c/o Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, New York 10036, my attorneys, each with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to receive the patent, to transact all business in the Patent and Trademark Office connected therewith and to file any International Applications which are based thereon under the provisions of the Patent Cooperation Treaty.

Please address all communications, and direct all telephone calls, regarding this application to.

John P. White _____ Reg No. 28,678
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
Tel. (212) 278-0400

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first joint inventor David M. Stern

Inventor's signature David Stern

Citizenship U.S.A. Date of signature 9/10/99

Residence 63 Tanners Road, Great Neck, New York 11020, U.S.A.

Post Office Address same as above

Full name of joint inventor (if any) Shi Du Yan

Inventor's signature Shu Yan

Citizenship U.S.A. Date of signature 9/10/99

Residence Apartment 4B, 60 Haven Avenue, New York, New York 10032, U.S.A.

Post Office Address same as above

Full name of joint inventor (if any)

Inventor's signature

Citizenship Date of signature

Residence

Post Office Address